Brazilian guidelines for the management of candidiasis – a joint meeting report of three medical societies: Sociedade Brasileira de Infectologia, Sociedade Paulista de Infectologia and Sociedade Brasileira de Medicina Tropical  by Colombo, Arnaldo Lopes et al.
OB
j
B
a
A
R
C
M
a
b
c
d
e
f
g
h
i
a
A
R
A
A
K
C
C
T
A
B
1
hbraz j infect d i s . 2013;17(3):283–312
The Brazilian Journal of
INFECTIOUS DISEASES
www.elsev ier .com/ locate /b j id
riginal article
razilian guidelines for the management of candidiasis – a
oint meeting report of three medical societies: Sociedade
rasileira de Infectologia, Sociedade Paulista de Infectologia
nd Sociedade Brasileira de Medicina Tropical
rnaldo Lopes Colomboa,∗,1, Thaís Guimarãesb,1, Luis Fernando Aranha Camargoa,1,
osana Richtmannc,1, Flavio de Queiroz-Tellesd,1, Mauro José Costa Sallese,1,
lóvis Arns da Cunhaf,1, Maria Aparecida Shikanai Yasudag,1, Maria Luiza Morettih,1,
arcio Nucci i,1
Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, Brazil
Hospital do Servidor Público Estadual de São Paulo (HC-FMUSP), São Paulo, SP, Brazil
Instituto de Infectologia Emilio Ribas/Pro-Matre-Santa Joana, São Paulo, SP, Brazil
Hospital de Clínicas, Universidade Federal do Paraná (UFPR), Curitiba, PR, Brazil
Santa Casa de Misericórdia de São Paulo, São Paulo, SP, Brazil
UFPR, Curitiba, PR, Brazil
Universidade de São Paulo (USP), São Paulo, SP, Brazil
Universidade Estadual de Campinas (UNICAMP), São Paulo, SP, Brazil
Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil
r t i c l e i n f o
rticle history:
eceived 14 February 2013
ccepted 16 February 2013
vailable online 18 May 2013
eywords:
a b s t r a c t
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Introduction
Importance of genus Candida in contemporary medicine
Among the fungi of medical interest, yeasts of the genus Can-
dida are of great importance because of the high frequency
that they colonize and infect human hosts. Candida species
are found in the gastrointestinal tract in 20–80% of healthy
adults. Approximately 20–30% of women have vaginal Candida
colonization.1 These commensal micro-organisms become
pathogenicwhen there are changes in themechanismsof host
defense or when anatomical barriers secondary to burns are
compromised or invasive medical procedures occur. Changes
in host defense mechanisms may be due to physiological
changes in childhood (prematurity) and aging but are more
often associated with degenerative diseases, malignancies,
congenital or acquired immunodeﬁciencies and immunosup-
pression induced by drugs and medical procedures.2
In the medical community, oral candidiasis and vaginitis
caused by Candida account for a signiﬁcant number of clini-
cal complaints brought to colleagues of different specialties.
Candida is the predominant genus among the yeasts of the
autochthonous microbiota of the oral cavity and other seg-
ments of the gastrointestinal tract. The prevalence of oral
cavity colonization by yeasts in normal individuals varies, but
most authors report rates of approximately 20–40% in the gen-
eral population.3 Among the 20 species of Candida of medical
importance, Candida albicans is the most prevalent yeast in the
oral cavity (accounting for more than 90% of isolates), along
with other sites of colonization by this fungus. If there is a dis-
ruption of local defense mechanisms, metabolic dysfunction
or the presence of diseases associated with immunosuppres-
sion, the colonized subject can develop infection and disease.1
Currently, oral candidiasis is the most prevalent opportunis-
tic infection among patients living with AIDS; it is considered
a marker of the progression of the immunological deterio-
ration that affects this population. Among treatment-naïve
patients infected with human immunodeﬁciency virus (HIV)
or those with no response to highly active anti-retroviral ther-
apy, episodes of oral candidiasis usually become recurrent and
may progress to esophagitis.4
Vulvovaginal candidiasis is the second leading cause of
infectious leucorrhea. It is responsible for approximately 13
million cases of vaginitis documented annually in North
American patients. Surveys reveal that 75% of women expe-
rience an episode of vaginal candidiasis during childbearing
years, with the estimation that 5% of these women have
recurrent episodes.5 Candida vulvovaginitis can be sporadic
or recurrent, and infections are termed primary or sec-
ondary according to the presence or absence of comorbidities
associated with this condition. Primary vulvovaginitis is
idiopathic and accounts for the vast majority of cases.
Secondary vulvovaginitis can have different causes, includ-
ing hormonal imbalances, metabolic disorders, medications
(i.e., antibiotics, contraceptives) and diseases associated with
6immunosuppression.
In the hospital environment, Candida infections account
for 80% of all fungal infections, including bloodstream, uri-
nary tract and surgical site infections. Pulmonary infections13;17(3):283–312
caused by Candida are poorly documented in clinical practice.7
Bloodstream infections are now a major challenge for tertiary
hospitals worldwide due to their high prevalence and mor-
tality rates.8 The incidence of candidemia in tertiary public
hospitals in Brazil is approximately 2.5 cases per 1000 hos-
pital admissions, a rate considered two to ten times higher
than those registered in European and American hospitals
and similar to the rates in neighboring countries.9–11 In addi-
tion to infection in the bloodstream, urinary candidiasis is
common in hospitalized patients. This laboratory ﬁnding is
controversial, as it may reﬂect different clinical possibilities
that range from a simple contamination of biological material
at the time of collection to a colonization of the urinary tract,
sepsis or localized invasive disease caused by Candida spp. In
most cases, candiduria involves colonization but not urinary
infection.12
Diversity of the genus Candida and its clinical relevance
The genus Candida has become recognized as the nomen con-
servandum, ﬁrst at the International Botanical Congress held
in Montreal in 1959. This genus consists of approximately 200
species, of which about 20 have been linked to cases of human
mycosis.2 Most of the yeasts have no known sexual form, and
identiﬁcation at the species level is obtained by analyzing their
micromorphological characteristics and biochemical proﬁles.
Morphological characterization of the majority of isolates of
this genus consists of the observation of its capacity to pro-
duce blastoconidia, pseudo-hyphae (sometimes true hyphae)
and eventually chlamydospores (C. albicans andCandida dublin-
iensis). In fact, Candida spp. have great genetic diversity and
distinct morphological and biochemical characteristics but
traditionally have been classiﬁed in the same genus.13
Despite the large number of Candida species already
described, the main species of clinical interest are C. albicans,
Candida parapsilosis,Candida tropicalis,Candida glabrata,Candida
krusei, Candida guilliermondii and Candida lusitaniae. However,
several cases of superﬁcial and invasive diseases and emerg-
ing species of Candida have been described, involving isolates
of C. dubliniensis, Candida kefyr, Candida rugosa, Candida famata,
Candida utilis, Candida lipolytica, Candida norvegensis, Candida
inconspicua, among others.14 Recently, molecular tools have
been used in the revision of the taxonomy. These tools are
essential for the characterization of some species as agents
of emerging infections in the human host, including C. dublin-
iensis, Candida pseudorugosa, Candida metapsilosis and Candida
orthopsilosis; these last two were associated with the complex
“psilosis”, formerly characterized as C. parapsilosis genotypes
I, II and III.15,16
C. albicans is undoubtedly the most frequently isolated
species of superﬁcial and invasive infections at different
anatomical sites and in studies worldwide. It is well known
as a potentially pathogenic yeast exhibiting pathogenicity and
virulence factors including the capacity to adhere to epithe-
lia and various mucous membranes, dimorphism-producing
ﬁlamentous structures that assist in tissue invasion, signiﬁ-
cant thermotolerance and the production of enzymes such as
proteases and phospholipases.17 This species is naturally sen-
sitive to all systemic antifungal drugs, but cases of acquired
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esistance to azoles have been reported in patients who have
rolonged exposure to these drugs; additionally, few isolates
esistant to echnocandins have been also reported.18 Resis-
ance to amphotericin B is considered anecdotal.19
C. dubliniensis has been recognized as a new species whose
orphological and biochemical characteristics are very sim-
lar to those of C. albicans. Molecular tests are needed to
ifferentiate the two species. This new species was ﬁrst
escribed in Ireland, where 17–35% of patients with HIV infec-
ion have oral colonization or infection with C. dubliniensis.20
n a Brazilian study that evaluated 548 yeast samples stored
n a mycology yeast collection, it was determined that 2%
f samples originally identiﬁed as C. albicans were actu-
lly C. dubliniensis.21 This emerging species seems to be less
athogenic than C. albicans, but it has a high probability of
eveloping resistance to azoles.22
C. parapsilosis is an important agent of candidemia and
s responsible for 15–30% of candidemias in most series
ublished in Brazil.9,23 In theNorthernHemisphere, the occur-
ence is higher among children and premature newborns, but
. parapsilosis in Brazil can be found in all age groups.24 The
requency of C. parapsilosis varies between public and private
ospitals in Brazil but is prevalent in the public setting.25,26
haracteristically, C. parapsilosis grows in glucose solution, has
reat capacity to produce “bioﬁlm” and often colonizes the
kinof healthprofessionals. Several studieshave reportedout-
reaks of candidemia due to C. parapsilosis associated with
he presence of a central venous catheter (CVC) and the use
f parenteral nutrition.27 Clinical isolates of this species are
sually sensitive to amphotericin B and triazoles.22 However,
ata generated by the SENTRY – a global candidemia surveil-
ance network – identiﬁed some samples of C. parapsilosis
esistant to ﬂuconazole.28 High minimum inhibitory concen-
ration (MIC) values for echinocandins have been described
gainst clinical isolates of C. parapsilosis. However, in most
ases, these values are stillwithin the range of susceptibility to
his class of drugs.29 In comparative clinical trials performed
ith caspofungin, micafungin and anidulafungin, the three
chinocandins available for clinical use, their therapeutic
esults for infections caused by C. parapsilosis were similar to
hose obtainedwith infections caused by C. albicans.30–32 Aside
rom a clinical study conducted by Moura-Duarte et al. that
bserved a higher number of cases of persistent candidemia
ue to C. parapsilosis in patients treatedwith caspofungin than
hose treated with amphotericin B, the rate of therapeutic
uccess obtained for infections caused by C. parapsilosis was
imilar to the rate for C. albicans infections.30 Thus far, in
his context, although some authors suggest that there is a
ossibility of rebound infections caused by C. parapsilosis in
atients exposed to echinocandins, data from clinical trials
ndicate that echinocandins have good efﬁcacy in C. parap-
ilosis infections.33–35 An important aspect to be considered
egarding C. parapsilosis is the recent change in the taxon-
my: due to the sequencing of different essential genes of
linical isolates of C. parapsilosis, Tavanti et al. characterized
he genetic heterogeneity of this taxon. As a result, “com-
lex psilosis” was reclassiﬁed to include three species: C.
arapsilosis, C. orthopsilosis and C. metapsilosis.15 The biological
ifferences that may be presented by species within the “com-
lex psilosis” are still not completely understood. However,3;17(3):283–312 285
the isolates from the three species may exhibit differences
in patterns of susceptibility to antifungal agents and bioﬁlm
production.16,36
C. tropicalis is a potential opportunistic agentwhen the host
is neutropenic and when there is suppression of bacterial
ﬂora due to antibiotic use and damage to the gastrointesti-
nal mucosa. C. tropicalis is the second or third most common
etiologic agent of candidemia in patients with cancer, par-
ticularly leukemia, and less frequently in patients with solid
tumors.37 In Brazil, unlike countries in Europe and in the
United States, C. tropicalis accounts for a substantial num-
ber of documented cases of candidemia in non-neutropenic
patients or patients with cancer.9,23,25,26,38,39 Clinical isolates
of this species are susceptible to amphotericin B and most
of the azoles. However, some authors have documented the
occurrence (usually <5%) of isolates resistant to ﬂuconazole.
Considering that this species has a strong phenomenon of
partial inhibition of growth in in vitro tests (trailing), there is
some doubt as to whether the rates of in vitro resistance to
ﬂuconazole are overestimated.40
C. glabrata has emerged as an important hospital pathogen,
representing the second or thirdmost common species among
the agents of candidemia reported in medical centers in
Europe and the United States.41 In Latin America, data gen-
erated from case series documented until 2005 show that the
isolation of C. glabrata candidemia accounted for no more
than 5–8% of all episodes of fungemia in public hospitals.9,42
Recently, data from cohorts of private hospitals and medi-
cal centers that perform large numbers of organ transplants,
where the practice of prophylaxiswith ﬂuconazole in high risk
patients seems to be more common, indicate that the preva-
lence of C. glabrata among the causative agents of fungemia
reaches more than 10% of the cases.43 Clinical isolates of
C. glabrata are less susceptible to ﬂuconazole. Most series
documented that 50% of C. glabrata strains have reduced
susceptibility to ﬂuconazole and that 10–20% of strains are
resistant to this drug.44 Consequently, increases in the rates
of colonization/infection by C. glabrata have been observed
in different groups of patients exposed to ﬂuconazole.45
In addition to therapeutic issues with azoles in infections
associated with C. glabrata, Pfaller et al. observed that iso-
lates of C. glabrata may have lower in vitro susceptibility to
amphotericin B and suggested the need for higher doses of
polienic for the treatment of invasive infections caused by
this agent.46 Another epidemiologic aspect of this pathogen
is its high prevalence in elderly patients. In a multicenter
study, which evaluated samples of candidemia in 17 med-
ical centers in the state of Iowa, it was observed that C.
glabrata is more prevalent in elderly patients and accounted
for 25% of all fungemias documented in patients over
65 years.47
C. krusei is an occasional hospital pathogen that is partic-
ularly isolated from patients with hematologic malignancies
and/orwhoare undergoing allogeneic hematopoietic stemcell
transplant (HSCT).48 Some authors reported increased occur-
rence of fungemias caused by C. krusei in neutropenic patients
37exposed to prolonged courses of ﬂuconazole. This yeast is
naturally resistant to ﬂuconazole, but in most cases, it is sen-
sitive to voriconazole (cross-resistance is uncommon in this
species).49
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Invasive infections caused by C. guilliermondii are still infre-
quent, although there are several case reports, especially in
patients with cancer.50 Despite the lack of information avail-
able in the literature, there are reports of in vitro resistance of
clinical samples of C. guilliermondii to amphotericin B, triazoles
and echinocandins. The clinical relevance of these in vitro data
is still debated; thus, clinical and laboratory monitoring of
patients treated with these drugs is recommended to identify
treatment failure.51
C. lusitaniae is infrequently a causative agent of invasive
disease but has been reported as a candidemia agent in
immunocompromised patients. From a total of 86 reported
cases of invasive disease by this species, 70 were identiﬁed
in patients with cancer. Often, clinical isolates of C. lusitaniae
have primary or secondary resistance to amphotericin B, but
they are very sensitive to all triazoles.52
The epidemiological and therapeutic peculiarities pre-
sented by different species of Candida spp. justify the need to
identify yeast at the species levelwhen thesemicro-organisms
are associated with systemic diseases. This procedure is fun-
damental for choosing the best therapeutic approach to be
administered to patients. In summary, it is important to note
that C. krusei isolates are completely resistant to ﬂuconazole
and that, more often than other species (except C. krusei), C.
glabrata samples canbe resistant to or can requirehigherdoses
of azoles for successful treatment. Likewise, higher doses of
amphotericin B should be used in the treatment of invasive
infections caused by C. krusei and C. glabrata. Finally, clinical
isolates of C. lusitaniae may be resistant to amphotericin B.28,46
In this context, it is important to recognize that, for the clin-
ician, the support of mycological diagnostics is essential for
the prevention, control and treatment of Candida infections.
Full identiﬁcation of yeast species is necessary; this infor-
mation is essential not only for the deﬁnition of therapeutic
choice but also for the control of hospital infection rates at dif-
ferent sites and during the investigation of outbreaks.1 In this
sense, it is important to know the wide range of manual and
automated commercial systems available that allow rapid and
accurate identiﬁcation of yeasts of clinical interest.53 These
guidelines suggest that all medical centers that treat patients
at risk for developing invasive fungal infections must have
a microbiology laboratory able to identify the main fungal
species of medical interest. There is no technical, medical
or administrative element that supports the clinical staff of
tertiary hospitals for working in medical centers without the
basic support of mycological diagnosis.
With regard to susceptibility testing, in view of discussions
concerning the existing clinical validation of cutoff points for
different therapeutic classes and the difﬁculty of access to this
test for most medical centers in Brazil, it is not possible to
recommend its universal use. Therefore, the best scientiﬁc evi-
dence available on clinical-laboratory susceptibility tests was
generated by in vitro assays performed with Candida species
and ﬂuconazole.44,54
Thus, the indication for antifungal susceptibility testing
has been evaluated in twodifferent scenarios: during epidemi-
ological investigation and while assisting the clinician at the
bedside. In the ﬁrst scenario, susceptibility tests are needed
for surveillance studies of species distribution and for moni-
toring MICs for different antifungal drugs in several hospital13;17(3):283–312
facilities. This allows us to identify and characterize temporal
trends and the geographic emergence of pathogens resistant
to different drugs, thus supporting a safe indication of empir-
ical therapy.55
While at the bedside, there are four indications for per-
forming susceptibility testing with azole: (a) to evaluate the
susceptibility to antifungal agents in patients with hematoge-
nous candidiasis with poor response to the drug in use,
information that, along with species identiﬁcation, is impor-
tant for guiding a possible change in regimen; (b) to evaluate
the susceptibility to ﬂuconazole in a sample of Candida spp.
isolated from invasive infections in the event that this triazole
was started empirically; (c) to shorten the time therapy started
with echinocandin or a lipid formulation of amphotericin
B, introducing sequential therapy with oral ﬂuconazole (de-
escalation); and (d) for superﬁcial infections with C. glabrata
or other Candida strains that may be resistant to ﬂuconazole
and to assess the possible in vitro activity of a new oral triazole,
such as voriconazole.56
If the medical center decided to make the clinical results of
in vitro antifungal susceptibility tests available, testing should
be performed by reference laboratories using standardized
methodology from regulatory authorities such as the CLSI and
EUCAST, or using methods known to be equivalent to these
tests, such as E-TEST and Vitek-2.57–60
Therapeutic options for infections caused by Candida spp.
During the last decade, the traditional therapeutic com-
pounds, consisting mainly of polienic, imidazole and
ﬁrst-generation triazoles, have been expanded with the devel-
opment and validation of new systemic antifungal agents.
Among the new antifungal agents active against Candida
spp. developed in the last decade, we highlight the second-
generation triazoles and a novel class of antifungal agents,
the echinocandins.
Polienic
Nystatin and amphotericin B are natural antifungals dis-
covered in the 1950s and obtained from aerobic bacteria
(Streptomyces noursey and Streptomyces nodosus, respectively)
that have broad-spectrum antifungal activities. In Candida
infections, nystatin is reserved for superﬁcial infections due
to its topical action. Amphotericin B is indicated for severe
forms of invasive candidiasis. The primary mechanism of
action is the interaction with steroid components of the cell
membranes of eukaryotic cells, leading to rupture. Other
mechanisms have been suggested, such as the production
of oxygen free radicals by phagocytes in the host. There
are different formulations of amphotericin B for intravenous
infusion: a deoxycholic acid formulation (amphotericin B
deoxycholate or conventional) and lipid formulations (col-
loidal dispersion, lipid complex and liposomal). The safest
lipid formulations in clinical use are amphotericin B lipid com-
plex and liposomal formulation; the latter has lower toxicity
and greater tolerability compared to the former formulation.61Conventional amphotericin B is primarily associated
with acute infusion events, including fever, chills, nausea,
vomiting, bronchospasm and rash. Fewer side effects are
experienced with the lipid complex formulation (two-hour
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nfusion) and particularly with the liposomal formulation
one-hour infusion). The most serious adverse effects are
elated to the nephrotoxicity of conventional amphotericin B,
ncluding the deterioration of renal, cardiac and hematopoi-
tic functions. Of these, renal failure is the most common,
ccurring in 12–80%, depending on the criteria adopted for
enal failure and the population evaluated.62 Among the var-
ous alternatives to reduce nephrotoxicity, hydration with
00mL of isotonic saline solution produces better results
ithout compromising effectiveness, but it can be limited
n critically ill patients.63 Among the lipid formulations of
mphotericin B, the liposomal formulation causes a lower
ncidence of nephrotoxicity.64,65
Amphotericin B is fungicidal and is active against vari-
us Candida species. Secondary resistance is rare. There are
ata suggesting that amphotericin B MICs for C. glabrata and
. krusei are higher, requiring the use of higher doses of
olienic. There is evidence that primary and/or secondary
esistance to amphotericin B can occur with clinical isolates
f C. lusitaniae.66,67
zoles
he azoles are a therapeutic class of great clinical util-
ty because of their broad spectrums of action (especially
oriconazole and posaconazole), their safety and the avail-
bility of oral and intravenous formulations (ﬂuconazole and
oriconazole). This therapeutic class can be divided into two
roups: the imidazoles and triazoles. The ﬁrst imidazole with
opical action, clotrimazole, was launched in 1960, and it is
till being used for superﬁcial candidiasis. In turn, the triazole
ompounds are subdivided into ﬁrst-generation (itracona-
ole and ﬂuconazole) and second-generation (voriconazole
nd posaconazole) compounds. Isavuconazole, a new second-
eneration triazole, is still under clinical investigation.68
The azole derivatives are characterized by their selective
nhibition of the production of ergosterol, a steroid found
n the fungal cell membrane. Their mode of action is the
nhibition of fungal 14--demethylase, a cytochrome p450-
ependent enzyme. Its catalyzing process is essential for the
onversion of lanosterol into ergosterol, other actions that
an contribute to the antifungal activity have been described,
uch as inhibition of the yeast transformation into mycelium,
he decrease in fungal cell adhesion and the accumulation
f steroids that are potentially toxic to fungal cells once the
onversion of lanosterol into ergosterol is blocked.69,70 Mech-
nisms of resistance related to drug efﬂux, as described with
. glabrata, invariably lead to cross-resistance. Mutations in
he gene ERG-11 and changes in the target enzyme 14--
emethylase, as described with C. krusei and ﬂuconazole,
ay not cause cross-resistance, as the second-generation tri-
zoles (voriconazole and posaconazole) have higher avidity
or the target enzyme.71 Recently, there has been discussion
egarding harmonization of the breakpoints of susceptibility
o ﬂuconazole, and the MIC value limit for susceptible strains
as decreased to 2g/mL for C. albicans, C. parapsilosis and C.
72ropicalis. Based on this change, higher rates of resistance to
uconazole are expected.73
Because the triazoles are cleared via the hepatic
etabolism, many drug interactions are possible.
H
i
S3;17(3):283–312 287
Ketoconazole
Ketoconazole was the ﬁrst imidazole developed for oral ther-
apy of fungal infections. It has a wide spectrum of action
against agents of dermatomycoses, endemic mycoses (includ-
ing paracoccidioidomycosis and histoplasmosis) and isolates
of Candida spp. Given its limited efﬁcacy in systemic fungal
infections in immunocompromisedhosts and its toxicity (hep-
atotoxicity and depression of steroidogenesis), this drug was
replaced by ﬂuconazole and itraconazole in most indications
(ﬁrst-generation triazole).69
Itraconazole
Itraconazole is a soluble triazole that is available in capsule
form. Its intravenous formulation and oral solution, both in
cyclodextrin, are not currently available in Brazil. Although
it can be used for infections caused by Candida, the primary
indication is for mild to moderate endemic mycoses, such
as paracoccidioidomycosis, histoplasmosis, coccidioidomyco-
sis, blastomycosis, chromoblastomycosis, phaeohyphomyco-
sis and sporotrichosis, in addition to dermatomycosis.74,75
Because it is well tolerated in long-term use, and consider-
ing its excellent availability in keratinized and subcutaneous
tissues, itraconazole can be used in chronic mucocutaneous
candidiasis and onychomycosis. It is considered as an alterna-
tive drug in cases of oral and vaginal candidiasis. Considering
that only the capsule formulation is available in Brazil, itra-
conazole is not indicated for treatment of hematogenous
candidiasis and other invasive forms of mycosis.76
Fluconazole
Fluconazole is a water-soluble triazole for parenteral (200mg)
and oral use (100mg and 150mg) that has antifungal activ-
ity against dermatophytes, Cryptococcus neoformans and most
Candida spp., except forC. krusei, whichhas primary resistance,
andC. glabrata, whichhas a lower susceptibility to ﬂuconazole,
particularly when isolated from patients with prior exposure
to this antifungal. Fluconazole has an excellent safety proﬁle,
good absorption in the gastrointestinal tract and distribution
in different compartments of the body, including the cen-
tral nervous system and the eyes. Fluconazole is effective in
the treatment of superﬁcial and deep infections by Candida
spp., including cases of oroesophageal candidiasis, hematoge-
nous candidiasis and candiduria and its complications.77 Most
cases of toxicity to ﬂuconazole are related to drug-induced
hepatitis andare oftenasymptomatic. GI intolerance isnot fre-
quent, and leukopenia and thrombocytopenia are rare. Unlike
ketoconazole, there is no blockage in hormonal synthesis with
ﬂuconazole. The dose should be reduced patients with creati-
nine clearance <50mL/min.78
Voriconazole
Voriconazole is a triazole available in tablets of 50mg and
200mg and vials of 200mg for intravenous administration
whose carrier is cyclodextrin. It has a broader spectrum of
action thanﬂuconazole, and it is active againstCandida species
that include C. glabrata and C. krusei, C. neoformans, Trichosporon
sp., Aspergillus spp., Fusarium spp., Scedosporium apiospermum,
istoplasma capsulatum, Blastomyces dermatitidis, Coccidioides
mmitis and Paracoccidioides brasiliensis. It is not active against
cedosporium proliﬁcans and agents of mucormycosis. The
i s . 20288 braz j infect d
oral formulation has good bioavailability and allows for
safe sequential therapy and therapeutic levels in different
tissues, including the central nervous system. Dose adjust-
ments are needed in cases of moderate hepatic impairment,
and the risks-beneﬁts should be measured in severe forms
of liver failure. Renal elimination of the active form is
minimal, with no need for dose adjustment when using
the oral formulation. However, the use of the intravenous
form must be evaluated on a case-by-case basis in patients
with creatinine clearance under 50mL/min, as the excipi-
ent (cyclodextrin) can be accumulated in patients with renal
failure. Regarding safety, the main adverse effects are tran-
sient visual disturbances (up to 30% of patients) reversible
with discontinuation of the drug, elevations of transaminases
and bilirubin, skin reactions and photosensitivity (up to 25%);
with use, it is recommended to avoid sun exposure and/or to
use sunscreen.79
In the treatment of esophageal candidiasis, voriconazole
has clinical efﬁcacy similar to ﬂuconazole. Although its use
is most important in invasive aspergillosis, in a study with
non-neutropenic patients with candidemia or invasive can-
didiasis, voriconazole exhibited similar efﬁcacy and less renal
toxicity compared to conventional amphotericin B followed by
ﬂuconazole.80,81
Posaconazole
Posaconazole is a triazole whose chemical structure has been
modiﬁed from the itraconazole molecule. This azole has a
broad antifungal spectrum that acts in vitro and in vivo against
isolates of Candida spp., including C. krusei and some isolates
of C. glabrata resistant to ﬂuconazole, Aspergillus spp., Fusarium
spp., dematiaceous fungi and some agents of mucormycosis.
To date, posaconazole is only available in an oral solution
that is administered three to four times per day. The absorp-
tion can decrease in certain conditions, such as when the
patient is receiving a proton pump inhibitor. An oral for-
mulation in tablet form with a single daily administration
and improved absorption and an intravenous formulation are
under development. While the main indication is prophy-
laxis of fungal infections in patients with acute myelogenous
leukemia andmyelodysplastic syndrome receiving remission-
inducing therapy as well as transplant recipients of allogeneic
hematopoietic stem cells with chronic graft-versus-host dis-
ease, the triazole treatment is also indicated as a rescue
treatment in several fungal infections, including oropharyn-
geal candidiasis. However, its unique availability in an oral
suspension formulation may be a limitation for patients who
are clinically unstable and/or with problems swallowing and
absorbing drugs that require oral treatment.82 This drug is not
yet available for clinical use in Brazil.
Echinocandins
Echinocandins are a new class of antifungal exclusively for
parenteral use that are classiﬁed as inhibitors of the enzyme
complex 1,3--d-glucan synthase, which synthesizes 1,3--d-
glucan, an essential polysaccharide component of the fungal
cell wall. The echinocandins are rapidly fungicidal for Can-
dida species and fungistatic for Aspergillus species.83 Currently,
three drugs represent this therapeutic class: caspofungin,
micafungin and anidulafungin.13;17(3):283–312
By acting on an exclusive structure of fungal cells (the
cell wall), the echinocandins are currently among the most
safe and well-tolerated drugs. When present, the adverse
effects are mild, such as fever, phlebitis at the infusion
site and transient elevation of liver enzymes. In addition to
fever, other symptoms mediated by histamine release may
rarely occur, including rash, facial swelling, pruritus, sensa-
tion of warmth and bronchospasm. Given the small hepatic
metabolism of these drugs, few (caspofungin and micafungin)
or no drug interactions (anidulafungin) occur with the use of
these drugs.83
Caspofungin
Caspofungin has been available for clinical use in Brazil for
almost a decade. Its formulation is available in vials of 50mg
and 70mg. The dose needed for invasive candidiasis is 70mg,
followed by 50mg daily. The elimination of the drug occurs
by spontaneous hydrolysis and acetylation in the liver; it does
not undergo oxidativemetabolismby the cytochromecomplex
P450-dependent enzyme, which explains its low interference
with other drugs metabolized in the liver. This antifungal has
no renal elimination; therefore, dose adjustment in patients
with renal failure is not indicated. In cases ofmoderatehepatic
failure, it is recommended to use a low dosage (35mg/day in
adults). There are no clinical data regarding its use in patients
with severehepatic impairment. It has gooddistribution indif-
ferent body ﬂuids and tissues, and its concentration is limited
in the cerebrospinal ﬂuid, urine and eyes.84 Caspofungin has
a large plasma protein binding capacity. This drug should not
be used in pregnant women, and there is little clinical infor-
mation regarding pediatric indications; however, case series
suggest that it is an effective and safe choice even in this
group.85 Caspofungin has been evaluated in patients with
candidemia and/or invasive candidiasis in a randomized trial
comparing conventional amphotericin B, which had the same
success rate and lower toxicity.30
Anidulafungin
This echinocandin is available in vials of 100mg. Among the
few randomized clinical trials available for this drug, two
studies have validated its clinical use in esophageal candidia-
sis and invasive candidiasis/candidemia, both in comparison
to ﬂuconazole. In the candidemia/invasive candidiasis study,
anidulafunginwasoneof the fewantifungal drugs that yielded
the best therapeutic result versus the comparator (ﬂucona-
zole) in a clinical study involving patients with candidemia.32
Experiences with anidulafungin in the pediatric popula-
tion, in which the safety and efﬁcacy of caspofungin and
micafungin have been demonstrated, are very limited.86,87
This echinocandin has less hepatic metabolism and may be
indicated for patients with moderate or severe hepatic impair-
ment without any need for dose adjustment.88
Micafungin
This drug has been sold in vials of 100mg for several years in
Japan and has recently begun being sold in the U.S. and Brazil.
Among the echinocandins, micafungin is the drug involved
in the largest number of phase II and III studies involving
patients with candidiasis. In candidemia and invasive can-
didiasis, studies were compared to liposomal amphotericin B
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Table 1 – Pharmacological aspects of systemic antifungals.
Name Tissue distribution Drug interactions Adverse events
Amphotericin B
and lipidic
formulations
Broad
High concentrations in lungs,
liver, spleen
Low concentration in CNS
Cyclosporine, aminoglycosides,
foscarnet, pentamidine,
antineoplastic (renal toxicity)
Infusion reactions (fever, chills,
hypotension, thrombophlebitis)
Renal toxicity (< lipidic
formulation)
Hypokalemia
Anemia
Itraconazole Broad
Low concentrations in saliva,
urine and CSF
Hepatic metabolism
Inhibitors of gastric acidity
(↓ absorption of itraconazole)
Rifampicin, carbamazepine,
phenytoin, phenobarbital (↓
serum)
Cyclosporine, terfenadine,
astemizole, cisapride, warfarin,
digoxin, lovastatin, simvastatin (↑
serum)
Nausea, vomiting
Increase in transaminases
Fluconazole Broad
High concentrations in CNS,
aqueous humor and prostate
Urinary clearance (active
metabolites)
Rifampicin, phenytoin,
carbamazepine (↓ level of
ﬂuconazole)
Nausea, vomiting
Transient Increase in
transaminases
Voriconazole Broad
High concentrations in CNS,
liver and adrenal cortex
Liver metabolism
Terfenadine, astemizole, cisapride,
ergot alkaloids, quinidine,
tacrolimus, cyclosporine,
omeprazole (↑ serum)
Sirolimus (↑ concentration of
voriconazole)
Rifampicin, carbamazepine and
phenobarbital (↓ concentrations of
voriconazole)
Transient visual disturbances
Transient Increase in
transaminases
Photosensitivity
Caspofungin Broad
Low concentrations in CNS and
urine
Cyclosporine (↑ caspofungin
concentration)
Rifampin, efavirenz, nevirapine,
phenytoin, dexamethasone,
carbamazepine (↓ caspofungin
concentration)
Reactions related to infusion (fever,
chills, rash, thrombophlebitis)
Transient increase in
transaminases
Anidulafungin Broad
Low concentrations in CNS and
urine
Not described
Micafungin Broad Itraconazole, sirolimus and
dipin
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nd caspofungina.31,89 Unlike other echinocandins, micafun-
in does not require a loading dose for treatment initiation.90
osage and drug interactions of antifungals
ables 1 and 2 show the pharmacological aspects and antifun-
al dosages for systemic use.
Below,we discuss the treatment ofmajor infections caused
y Candida. The recommendations for therapy are indicated
or adult patients andwere based on levels of evidence accord-
ng to the strength of the recommendation and the quality of
vidence from the American Society of Infectious Diseases,
dapted from the Canadian Ministry of Health,91 as shown in
able 3.Each topography was discussed with regard to epidemi-
logical, clinical and laboratory diagnostic and therapeutic
ecommendations. The therapeutic options for treating can-
idiasis are summarized in Table 4.e
)
Treatment
Oral candidiasis
Epidemiological aspects
Oral candidiasis is considered superﬁcial candidiasis that
affects patients with changes in local or systemic immu-
nity, either due to age (premature neonates and the
elderly), prosthesis use, exposure to immunosuppressive
drugs (chemotherapy, corticosteroids), antibiotics or the
presence of diseases such as cancer, diabetes, sarcoidosis,
cirrhosis, malnutrition, xerostomy and AIDS.92 In clinical
practice, most cases of candidiasis are observed in pediatric
patients, who exhibit immaturity of the defense mechanisms
of the mucosa, and the elderly, whose defense mecha-
nisms are senescent or even because of the use of dental
prostheses.93 The pathological conditions most commonly
290 braz j infect d i s . 2013;17(3):283–312
Table 2 – Antifungal dosages in humans based on renal function.
Name Regular dosage Cl > 50 Cl between 10 and 50 Cl < 10
Amphotericin B 0.5–1mg/kg/day QD 0.5–1mg/kg/day QD 0.5–1mg/kg/day QD
Amphotericin B
Lipidic
formulation
3–5mg/kg/day QD 3–5mg/kg/day QD 3–5mg/kg/day QD
Itraconazole 100–200mg/day BID 100–200mg/day BID 100–200mg/day BID
Fluconazole 800mg/day BID – 1 day (leading dose)
200–400mg/day BID
400mg/day BID – 1 day (leading dose)
100–200mg/day BID
400mg/day BID – 1 day (leading dose)
100–200mg/day QD
Voriconazole 6mg/kg/day BID – 2 days (leading
dose)
4mg/kg/day BID (maintenance)
6mg/kg/daya BID – 2 days (leading
dose)
4mg/kg/day BID (maintenance)
6mg/kg/daya BID – 2 days (leading
dose)
4mg/kg/day BID (maintenance)
Caspofungin 70mg/day QD – 1 day (leading dose)
50mg/day QD (maintenance)
70mg/day QD – 1 day (leading dose)
50mg/day QD (maintenance)
70mg/day QD – 1 day (leading dose)
50mg/day QD (maintenance)
Anidulafungin 200mg/day QD – 1 day (leading dose)
100mg/day QD (maintenance)
200mg/day QD – 1 day (leading dose)
100mg/day QD (maintenance)
200mg/day QD – 1 day (leading dose)
100mg/day QD (maintenance)
Micafungin 100mg/day QD 100mg/day QD 100mg/day QD
Cl, creatinine clearance (mL/min).
a Avoid the use of IV voriconazole in patients with creatinine clearance <5
formulation in cases of renal failure.
Table 3 – Strength of recommendation and quality of
evidence.
Category Deﬁnition
Strength of recommendation
A Strong evidence to support recommendation
B Moderate evidence to support recommendation
C Poor evidence to support recommendation
Quality of evidence
I Evidence of ≥1 randomized controlled clinical trial
II Evidence of ≥1 well-designed clinical trial, not
randomized, cohort or case–control studies
(preferably more than one center), or multiple sets
of results of uncontrolled studiesIII Evidence based on expert opinion or clinical
experience, descriptive studies or committee reports
associated with oral candidiasis in adult patients are AIDS,
diabetes and exposure to antibiotics and/or corticosteroids for
different conditions. Therefore, all adult patients presenting
with oral candidiasis without obvious cause should be inves-
tigated for HIV infection.94
C. albicans accounts for approximately 90% of the isolates
causing oroesophageal candidiasis, but C. tropicalis, C. kru-
sei, C. glabrata, C. parapsilosis and C. dubliniensis can also be
detected.95 In AIDS patients unresponsive to antiretroviral
therapy, episodes of oropharyngeal candidiasis become recur-
rent, requiring prolonged use or repeated cycles of therapy
with triazoles. In this scenario, there is an increase in episodes
of candidiasis by Candida non-albicans isolates resistant to ﬂu-
conazole or even in the risk of selecting resistant strains of C.
albicans to this drug.96Clinical and laboratory diagnosis
Clinical manifestations are varied and depend on the host’s
immune status and the extent of oral candidiasis. The largest0mL/min (toxicity risk). There are no restrictions for use of the oral
clinical experience of infectious disease is in the form of
pseudomembranous candidiasis. The most common symp-
toms are oral discomfort, burning pain and the presence
of removable white plaque under erythematous mucosa.
These conditions make feeding difﬁcult, and they can com-
promise the regularity of oral drug treatments.97 However,
other clinical presentations are known. Erythematous can-
didiasis presents itself as erythematous inﬁltratewith reduced
papillae when present on the tongue. Patients using dental
prostheses with oral candidiasis have chronic erythema and
discomfort in the region of the prosthesis. Angular cheilitis
caused byCandida spp.manifests as discomfort, erythema, and
ﬁssures in the angular region of the lips.98
The clinical presentation is usually very characteristic of
this condition, particularly when it is pseudomembranous.
However, clinical diagnosis should be conﬁrmed by laboratory
investigation as follows: (a) bydirectmycological examination,
with scrapes of lesions in KOH preparations or by Gram stain-
ing, where the specimen is analyzed by the presence of fungal
elements consistent with Candida spp. and/or (b) by culturing
in selective fungal medium (preferably chromogenic medium
to identify different species), where the yeast is isolated and
the agent is forwarded to complete identiﬁcation.99
Culture is particularly important in cases of recurrent can-
didiasis in patients with AIDS, in cases of poor response to
conventional therapy or when an injury that is suggestive of
candidiasis arises in patients receiving any antifungal drug.
In these situations, the identiﬁcation of the agent species and
testing for susceptibility to antifungal agents are necessary
recommendations for optimizing a new therapeutic indica-
tion in view of the possibility of infection by strains of Candida
spp. resistant to one or all triazoles.100,101Therapeutic recommendations
The goal of treatment is to eliminate the signs and symptoms
of the disease, reduce or eliminate colonization and prevent
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Table 4 – Therapeutic regimens for candidiasis.
Site Therapy Level of
evidence
Comments
Oral candidiasis Topic
Nystatin 100,000–400,000UI/mL or 4–6mL 4–5 times/day
for 14 days
B-II Low tolerance and high levels of sugars,
such as in vehicles (cariogenic potential
and caution in diabetics)
Systemic
Fluconazole PO 200mg at ﬁrst day and 100mg/day for
7–14 days
A-I
Itraconazole PO 200mg BID with food for 7–14 days A-II Therapy with capsules has the
disadvantage of absorption problems and
reduced exposure of the antifungal agent
in saliva
Voriconazole 200mg BID for 7–14 days B-II
Esophageal
candidiasis
Fluconazole PO or IV 200mg in the ﬁrst day followed by
100mg/day for 14–21 days
A-I
Voriconazole 200mg BID for 14–21 days A-I Use in the treatment of oropharyngeal
candidiasis refractory to ﬂuconazole is
based on studies in vitro, but there is little
documentation of their clinical success in
this speciﬁc condition
Itraconazole 200mg PO BID with food for 14–21 days B-II Therapy with capsules has the
disadvantage of absorption problems and
reduced exposure of the antifungal agent
in saliva
Amphotericin B deoxycholate 0.3–0.5mg/kg/day IV for
7–14 days
B-II
Caspofungin 50mg/day IV or anidulafungin 200mg/day
IV or micafungin 150mg/day IV for 7–14 days
A-I
Vulvovaginal
candidiasis
Topical
Topical therapy with azoles for 3–7 days or nystatin for
10–14 days:
A-I The treatment of sexual partners is not
recommended in uncomplicated cases
but may be considered in women with
recurrent formButaconazole 2% cream, 5 g/day
Clotrimazole 1% cream, 5 g/day
Clotrimazole vaginal tablets, 500mg/day
Miconazole 2% cream, 5 g/day
Miconazole 100mg, 200mg or 1200mg (single dose)
vaginal suppositories
Econazole 150mg tablets or suppository
Terconazole 0.4% or 0.8% cream, 5 g/day
Terconazole vaginal suppositories, 80mg
Nystatin vaginal tablets, 100,000UI (for 10–14 days)
Systemic
Fluconazole single dose 150mg PO
A-I
Itraconazole PO 200mg/day for 3 days or 400mg PO
single dose
B-II
Complicated dose
Fluconazole 150mg/day repeated 2–3 times 72h apart A-I
Itraconazole 200mg/day for 3 days B-II See dosage and formulation in the text
Recurrent cases A-I
Suppressive therapy for 6 months with triazoles B-I
Therapy with vaginal suppositories of boric acid
600mg/day for 14 days is indicated for recurrent
candidiasis caused by Candida glabrata
Urinary candidiasis Fluconazole IV or PO 200mg/day for 7–14 days A-I These regimens are reserved for
refractory cases or cases intolerant to a
ﬂuconazole and for yeasts that are
resistant to this azole
Systemic amphotericin B 0.3mg/kg to 1mg/kg/day for
1–7 days
B-II
Amphotericin B in bladder irrigation, 50mg/day for
48–72h in a continuous infusion with a 2-way catheter
B-II
Peritoneal candidiasis
related to dialysis
Systemic amphotericin B 0.7–1mg/kg/day B-II Treatment period must be four to six
weeks.
Fluconazole IV or PO 400mg/day B-II
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Table 4 – (Continued)
Site Therapy Level of
evidence
Comments
Postoperative peritoneal
candidiasis
Systemic amphotericin B 0.7–1mg/kg/day B-II
Fluconazole IV or PO 400mg/day B-II
Echinocandins B-I
Respiratory tract
candidiasis
Upon conﬁrmation of a diagnosis of pneumonia, the
choice of antifungal should be made as discussed in the
section on acute disseminated candidiasis; there may
be choice between echinocandins, ﬂuconazole or
amphotericin B formulations
B-II The ﬁnding of a positive culture for
Candida spp. in respiratory tract samples
should be taken as evidence of
colonization of this site, where the risk of
pneumonia is generally low
Hematogenous
candidiasis
Non-neutropenic patients
Anidulafungin IV 200mg at ﬁrst day followed by
100mg/day IV
A-I
Caspofungin 70mg IV at ﬁrst day followed by 50mg/day
IV
A-I
Micafungin EV 100mg/day A-I Considered for sequential therapy to
complete the minimum period of 14 days
of treatment after the deﬁnition of the
agent and upon favorable documentation
of clinical response to treatment with
echinocandins. Medical centers with
rates of incidence exceeding 10% of
ﬂuconazole-resistant strains should not
use ﬂuconazole in any patient before the
identiﬁcation of the agent
Fluconazole IV 800mg/day at ﬁrst day followed by
400mg/day
B-I
Amphotericin B liposomal formulation 3mg/kg/day B-I A liposomal formulation and
amphotericin B are alternatives for
patients who are not responsive to
echinocandins, who are intolerant to the
therapeutic class or who develop
endocarditis or meningitis
Amphotericin B in lipidic complex from 3mg/kg/day to
5mg/kg/day
B-II The duration of antifungal therapy
should be at least 14 days after negative
cultures and the disappearance of signs
and symptoms related to hematogenous
candidiasis
Hematogenous
candidiasis
Neutropenic patients
Echinocandins A-I The doses and treatment time should
meet the same criteria established for
non-neutropenic patients
Amphotericin B liposomal formulation B-I
Amphotericin B in lipidic complex B-II
Evidence of endophthalmitis
Fluconazole B-III
Voriconazole B-III
Antifungal therapy is recommended for a
period of four to six weeks, with
monitoring by an ophthalmologist for
further characterization of the treatment
time and treatment response
Evidence of endocarditis
Amphotericin B in lipidic complex (1st choice) B-II
Echinocandins (alternative) B-II
Fluconazole (sequential use) B-II
Chronic disseminated candidiasis B-II
Amphotericin B deoxycholate 0.6–0.7mg/kg/day B-II Fluconazole should be used when Candida
species are susceptible and the patient is
clinically stable, always after a long
period of treatment with formulations of
amphotericin or echinocandin
Amphotericin B lipid complex 3–5mg/kg/day B-II Valve replacement is recommended, and
systemic therapy should continue for at
least six weeks after valve replacement
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Table 4 – (Continued)
Site Therapy Level of
evidence
Comments
Fluconazole 6mg/kg/day in stable and non-neutropenic
patients, with no previous use of ﬂuconazole
B-II
Echinocandins in regular dosage The antifungal should be used until
complete resolution of the abscesses
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•ecurrence.92 Topical therapy is recommended for patients
ithout HIV/AIDS (B-I) and for the initial episodes of crypto-
occosis in patients with HIV/AIDS (A-I).
opical therapy (uncomplicated infection)
ystatin 100,000–400,000 IU/mL and 4–6mL four to ﬁve times a
ay for 14 days (B-II) should be administered. Successful treat-
ent depends on the time of contact with the oral mucosa for
t least two minutes. It is worth mentioning that this drug
as a low tolerance and high sugar content as a vehicle. It also
as cariogenic potential and should be used with caution in
iabetic patients.98
In theU.S. andEurope, anoral clotrimazole solution is avail-
ble for use three to ﬁve times a day for 14 days (B-II). In
hese countries, topical therapy is the rule inmild and/or early
andidiasis, even in patients with AIDS.102 Unfortunately, in
razil, clotrimazole is not available in formulations suitable
or oral use. In this context, in view of the difﬁculties in
andling nystatin, topical therapy is restricted to only a few
atients.
ystemic therapy
he best therapeutic option for systemic candidiasis is oral
uconazole; the other options are considered only in patients
nresponsive or intolerant to this drug (A-I).100 Fluconazole
00mg PO in the ﬁrst day and 100mg/day for 7–14 days (A-I).
In patients with oropharyngeal candidiasis refractory to
uconazole, the options are as follows:
Itraconazole 200mg orally BID with food for 7–14 days
(A-II).103,104 Considering that in Brazil we do not have an
oral solution, capsules have the disadvantage of impaired
absorption and less exposure of the antifungal agent in
saliva (B-III).
Voriconazole 200mg BID for 7–14 days. This drug has been
validated in comparative clinical trials with ﬂuconazole
in patients with esophageal candidiasis (A-I).105 Its use in
oral therapy for oropharyngeal candidiasis refractory to
ﬂuconazole is based on in vitro studies, but with limited
documentation of their clinical success for this speciﬁc con-
dition (B-II).
Posaconazole 200mg PO on the ﬁrst day followed by 100mg
orally QD for 13 days for primary therapy (A-I) or 400mg TID
for 3 days, followed by 400mg QD for 25 days for refractory
cases (B-II). This drug has been validated for this indica-
tion in two clinical trials: a randomized comparison with
ﬂuconazole and an open study for refractory cases.106,107 Itsidentiﬁed in imaging
indication should be reserved for cases of poor response to
ﬂuconazole (B-I). This drug is not available in Brazil.
• Amphotericin B deoxycholate 0.3–0.5mg/kg/day IV for 7–14
days (B-II).108 This drug should be reserved for cases refrac-
tory to ﬂuconazole (B-II).
• Caspofungin 50mg/day IV or anidulafungin 200mg/day IV
or micafungin 150mg/day IV for 7–14 days. These drugs
have been validated in clinical trials comparing ﬂucona-
zole in patientswith esophageal candidiasis (A-I).109–111 The
use of these drugs should be reserved for treatment of
esophageal candidiasis refractory to ﬂuconazole (B-I).
Given that oral candidiasis is related to the imbalance
between the colonizing agent and the local or systemic
defense mechanisms, we should try to act toward control of
the underlying disease and/or removal of the predisposing
conditions. Otherwise, the trend favors chronicity of the pro-
cess, as it occurs in patients with prostheses and AIDS that is
unresponsive to antiretroviral therapy.
Esophageal candidiasis
Epidemiological aspects
Esophageal candidiasis is considered a form of semi-invasive
candidiasis that primarily affects patients with AIDS, can-
cer, diabetes, previous esophageal diseases, malnutrition and
alcoholism, along with those in therapies using corticoste-
roids, antibiotics, H2 receptor antagonists and proton-pump
inhibitors.92 In clinical practice, most cases of esophageal
candidiasis occur in AIDS patients, followed by lower frequen-
cies of diabetics and critically ill patients exposed to multiple
antibiotic cycles.99
Clinical and laboratory diagnosis
Candida esophagitis can be oligosymptomatic, but its main
clinical manifestations include dysphagia, odynophagia and
retroesternal burning. In children, nausea, vomiting and
dehydration are the main signs. Although the presence of
concomitant oral and esophageal candidiasis is common, par-
ticularly in AIDS patients, the absence of oral candidiasis
doesnot excludeesophagitis diagnosis. Complications include
bleeding, perforation and stenosis.101
In AIDS patients, the diagnosis is usually made based only
on clinical data and treatment response. However, taking into
account many other opportunistic diseases that affect the
esophagus in immunocompromised patients (e.g., herpes and
cytomegalovirus), laboratory investigation is mandatory for a
deﬁnitive diagnosis.94 Endoscopy reports often reveal white
plaques that may or may not be accompanied by ulcerated
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lesions. Apart from the morphological ﬁndings, it is rec-
ommended to perform a scrap (brush) to obtain a sample
for microscopic examination and culturing, in addition to a
mucosal biopsy.99
The microscopic examination of fungal elements is per-
formed with a sample obtained by scraping on a slide with
KOH or by Gram stain. The culture is performed with a sample
obtained by scraping or biopsy. A biopsy should be processed
with hematoxylin–eosin staining and silver methenamine
(Grocott).99
The deﬁnitive diagnosis of esophageal candidiasis is made
when, in addition to the clinical and morphological endo-
scopic ﬁndings, we identify fungal elements on microscopic
examination and/or observe the presence of fungal elements
in tissue, conﬁrming invasion by the pathogen. From an aca-
demic point of view, the isolated identiﬁcation of Candida in
culture but no fungal elements by microscopic examination
and biopsy may represent colonization of the gastrointestinal
tract and not infection.101
Therapeutic recommendations
Systemic therapy is recommended for cases of esophageal
candidiasis (B-II). This starts with empirical systemic therapy
(A-I) with ﬂuconazole 200mg PO or IV in the ﬁrst day, followed
by 100mg QD for 14–21 days (A-I). When endoscopy is not per-
formed at the time of diagnosis, it should be performed if no
improvement occurs within 3–5 days.95
In patients with esophageal candidiasis refractory to ﬂu-
conazole, the options are as follows:
• Voriconazole 200mg BID for 14–21 days. This drug was
validated in a comparative clinical trial with ﬂuconazole
in patients with esophageal candidiasis (A-I).105 Its use in
the treatment of esophageal candidiasis refractory to ﬂu-
conazole may have a compromised result due to eventual
cross-resistance; however, it is a good indication for suscep-
tibility tests, if available (B-II).
• Itraconazole 200mg PO BID with food for 14–21 days (A-
II).103,104 Given that there is no oral formulation in Brazil and
cross-resistance is commonly observed across triazoles,
treatmentwith capsules presents problemswith absorption
and lesser exposure of the drug to the saliva. These factors
can compromise treatment success.
• Posaconazole 200mg PO on the ﬁrst day followed by 100mg
POQD for 13 days for primary therapy (A-I), or 400mgBID for
3 days followed by 400mgQD for 25 days for refractory cases
(B-II). This drug was validated for this indication in two clin-
ical trials: one controlled and randomized with ﬂuconazole
and another open-label for refractory cases.106,107 Its use
for esophageal candidiasis refractory to ﬂuconazole may be
compromised by an eventual cross-resistance; however, it is
a good indication for susceptibility tests, if available (B-II).
This drug is not available in Brazil.
• Amphotericin B deoxycholate 0.3–0.5mg/kg/day IV for 7–14
days (B-II).108
• Caspofungin 50mg/day IV or anidulafungin 200mg/day
IV or micafungin 150mg/day IV for 7–14 days. These
drugs were validated in comparative clinical trials with
ﬂuconazole in patients with esophageal candidiasis
(A-I).109–11113;17(3):283–312
Vulvovaginal candidiasis
Epidemiological aspects
Vaginal candidiasis is highly prevalent in women during their
childbearing life; approximately 75% have at least one episode
lifelong, and 5–10% can develop a recurrence (deﬁned as at
least four episodes of vaginitis by Candida spp. within one
year).112
Themost frequent predisposing factors for vaginal candidi-
asis include exposure to high levels of estrogens (birth control,
pregnancy and hormone replacement), uncontrolled diabetes
mellitus, use of topical and systemic antibiotics and inadequate
hygiene habits. Most women with recurrent vaginal candidia-
sis do not have underlying diseases associated with systemic
immunosuppression, and recurrence may be secondary to a
deﬁciency in the local immune response to the agent.113
Vulvovaginal candidiasis is usually classiﬁed as compli-
cated or uncomplicated, pending on the severity of the clinical
presentation and basic conditions of the host. Uncomplicated
forms of vaginitis account for more than 90% of cases and
have an excellent response to short oral or topical therapy.
Patients with more complicated vaginitis require a prolonged
antimycotic therapy.114
C. albicans is the most frequent cause of vaginitis, account-
ing for approximately 74–95% of cases, followed by C. glabrata
in approximately 14.5% of cases. The non-albicans species are
more common in recurrent forms andmay be found in 10–20%
of these patients. C. glabrata is the species most frequently
identiﬁed in these cases.115,116
Clinical and laboratory diagnosis
Considering that 30% of women may have Candida coloniza-
tion and there is a wide differential diagnosis for infectious
leukorrhea, the diagnosis of C. vulvovaginitis should be based
on clinical and laboratory ﬁndings.117
Candidiasis involves the vulva and the vaginal lumen,
causing intense itching, burning, local discomfort, dysuria,
vaginal discharge and dyspareunia. Clinical examination
revealed swelling and redness of the vulva and/or vagina,
vaginal discharge that looks like milk and, eventually, vulvar
carved cracks.118
Clinical diagnosis must be performed by the following
tests:117
• Direct microscopic examination with the addition of KOH
(10%) or Gram stain to search for fungal elements, comple-
mented by evaluation of the vaginal pH (infection usually
occurs with a pH between 4 and 4.5);
• Culture in speciﬁcmaterial. To decrease costs, someauthors
recommend prompt culture only for complicated or recur-
rent vulvovaginal candidiasis.
Therapeutic recommendations
Non-complicated vulvovaginal candidiasis. Topical therapy:
although most patients prefer oral medications, a meta-
analysis comparing 17 studies of uncomplicated vulvovaginal
candidiasis revealed similar efﬁcacy between oral and vagi-
nal drugs.119 There is evidence that topically applied azole
therapy over a period of 3–7 days is more effective than nys-
tatin, with improvement of symptoms and negative cultures
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n 80–90% of patients who completed therapy (A-I). Generally,
igher concentrations and doses of topical medications are
ffective over a period of 3 days. Lower doses of the same for-
ulations require more prolonged therapy.102 The options for
opical therapy are numerous and include the following:
Butaconazole 2% cream, 5 g/day;
Clotrimazole cream 1%, 5 g/day;
Clotrimazole vaginal tablets, 500mg/day;
Miconazole 2% cream, 5 g/day;
Miconazole, 100mg, 200mgor 1200mg (single dose), vaginal
suppositories;
Econazole, 150mg, tablet or suppository;
Terconazole 0.4% or 0.8% cream, 5 g/day;
Terconazole, 80mg, vaginal suppositories;
Nystatin, 100,000 IU vaginal tablets (10–14 days).
There are formulations containing combination therapy
ith other agents that will not be commented upon in the
ext:
Systemic therapy: the use of oral triazoles is a safe and efﬁ-
cient alternative to topical therapy. There is a large amount
of clinical experience in treating vulvovaginal candidiasis
with ﬂuconazole 150mg QD, single dose (A-I).102 Another
option to this drug is itraconazole 200mg QD for 3 days or
400mg single dose (B-II).120 Systemic therapy with triazoles
is not indicated in pregnant women. The treatment of sex-
ual partners is not recommended in uncomplicated cases
but may be considered in recurrent cases.121
omplicated vulvovaginal candidiasis.
Moderate and severe cases and/or immunocompromised
patients: prolonged topical and systemic therapy should be
administered to these patients. Topical therapy is recom-
mended for at least 7–14 days using any of the formulations
listed above (A-I).102 In case of systemic therapy, the follow-
ing drugs can be considered:
◦ Fluconazole 150mg/day, repeated two or three times 72h
apart (A-I);
◦ Itraconazole 200mg/day for 3 days (B-II).
ecurrent vulvovaginal candidiasis.
If the diagnosis of recurrent vulvovaginal candidiasis is
made and if there is no identiﬁcation of or possibility to con-
trol or remove the triggering factors, suppressive therapy
with triazoles for sixmonths is an effective controlmeasure
for recurrent episodes (A-I).122
In such patients, attack therapy can be administered with
any of the topical formulations listed above for 7–14 days
(A-I) or ﬂuconazole 150mg/day each 72h (days 1, 4 and 7) or
until complete symptoms remission; this is the preferred
regimen in clinical practice. Once the initial episode is con-
trolled, maintenance therapy with ﬂuconazole 150mg/day
122once a week for six months is indicated (A-II).
Although the largest clinical experience of suppressive ther-
apy for recurrent candidiasis was with ﬂuconazole (A-I),
there are published trials that suggestmaintenance therapy3;17(3):283–312 295
with clotrimazole 500mg suppositories twice aweek or itra-
conazole (200mgPO twice aweekor 200mgPOBIDmonthly)
(B-I).123,124
• Cases of vulvovaginal candidiasis caused by C. glabrata may
not respond to ﬂuconazole. In these cases, vaginal suppos-
itories of boric acid 600mg/day for 14 days are indicated
(B-I).125
Urinary candidiasis
Epidemiological aspects
The term candiduria refers to the growth of Candida spp.
in urine cultures collected by appropriate techniques; this
ﬁnding is not necessarily accompanied by signs and/or
symptoms of urinary tract infection (UTI). Candiduria is
very frequent among patients exposed to risk factors; up
to 20% of hospitalized patients may have candiduria dur-
ing their hospitalization, particularly intensive care unit
(ICU) patients.126,127 This laboratory ﬁnding fosters dilemmas
regarding its interpretation, as it can represent a simple con-
tamination of the urine collection, candiduria asymptomatic
cystitis or pyelonephritis, primary renal candidiasis, uretero-
pelvic fungus ball or disseminated candidiasis with renal
manifestations.
Among hospitalized patients, the factors most often
related to the development of candiduria are advanced
age, female gender, broad-spectrum antibiotics, the use
of corticosteroids and immunosuppressive drugs, the pres-
ence of urinary tract abnormalities, diabetes, delayed
vesical catheterization, postoperative of major surgery and
malignancies.127,128
Series of cases from Brazil conﬁrm that the three most
prevalent species isolated from urine in hospitalized patients
are C. albicans, C. tropicalis and C. glabrata. These studies mea-
sure prevalences ranging from 35.5 to 70% for C. albicans,
4.6–52.5% for C. tropicalis and 7–8.8% for C. glabrata.129–132
Clinical and laboratory diagnosis
In outpatients not exposed to the risk factors mentioned,
in most cases, the identiﬁcation of Candida in urine reﬂects
inadequate collection or processing of the sample and con-
sequent contamination of the culture. In patients exposed to
risk factors for UTI by Candida, the ﬁnding of candiduria may
signify colonization or infection. In these patients, the count-
ing of colonies is highly variable and directly dependent on
the methodology used to collect material. Thus, the isolation
of Candida in the urine may occur even in the absence of dis-
ease, and there is considerable controversy regarding the value
of colony counts obtained in culture, a procedure with low
speciﬁcity and sensitivity in differentiating between patients
colonized and infected by this agent.12
Some authors suggest that there is a greater rela-
tionship between candiduria and UTI when the colony
count in the urine culture reaches values of approximately
10,000–100,000CFU/mL.133,134 However, scores below that can
bemeasured in patientswithCandidaUTI, particularly in cases
of pyelonephritis acquired by the hematogenous route due
to systemic candidiasis, in which the kidneys function as ﬁl-
ters and may reﬂect low counts in the urine. In this sense,
there is no consensus among authors on the speciﬁc cutoff
i s . 20296 braz j infect d
value for the interpretation of quantitative urine cultures for
the recognition of patients with infection of the lower UTI or
pyelonephritis.135
Therapeutic recommendations
• The best therapeutic approach for patients with candiduria
should be deﬁned on individual basis, considering clinical
and epidemiological data to classify each patient into one
of the following conditions: (1) no prior risk factors for can-
diduria, (2) exposure to risk factors but unlikely to be a case
of disseminated candidiasis, or (3) exposure to risk factors
for candiduria with septicemia without deﬁning etiology
and possible/probable systemic dissemination.102,12
• The therapeutic approach suggested for these three differ-
ent scenarios are the following. (1) No prior risk factors
for candiduria: in this category, we have patients without
underlying diseases who did not undergo catheterization
and who have no history of previous use of corticoste-
roids and antibiotics. They should not receive systemic
antifungal agents. It is recommended to request a new
collection of material and, if yeasts are found, to inves-
tigate the possibility of fungal genital mucositis in the
vagina or the glans (C-III).136 (2) Predisposed to candiduria,
but unlikely to be disseminated candidiasis: this cate-
gory includes asymptomatic outpatients or inpatients who
underwent catheterization and/or other predisposing fac-
tors for candiduria. In these patients, the initial approach
is the removal of the predisposing factors with subsequent
clinical and laboratory follow-up (C-III). In the vast major-
ity of patients, candiduria resolves after the introduction
of these measures. Patients with symptoms of cystitis and
with positive urine for yeasts should be treated with anti-
fungal agents (B-III).102,136 (3) Predisposed to candiduria
with probable systemic dissemination: critically ill patients
with risk factors for systemic fungal infection and who
evolve with candiduria and signs of sepsis should be inves-
tigated for invasive candidiasis (blood) and should begin
the use of systemic antifungal drugs. This means that the
patient is not merely colonized (C-III).102
• If there are indications for treatment, treatment regimens
include the following:
– Fluconazole, oral or intravenous dose of 200mg/day for
7–14 days (A-I).137
– Amphotericin B, systemic dose of 0.3mg/kg to
1mg/kg/day for 1–7 days (B-II) or amphotericin B,
bladder irrigation, 50mg/day for 48–72h with continuous
infusion in a two-way tube (B-II). These schemes are
reserved for cases refractory infections or those intol-
erant to ﬂuconazole, along with yeasts resistant to this
azole.102,138
– In case of suspicion of systemic candidiasis, the patient
should be treated according to the recommendations for
hematogenous candidiasis.102
– Clinical experiencewith candiduria andechinocandins or
voriconazole is restricted; pharmacological data suggest
that the urinary concentrations of both antifungals are
reduced.139
– In the clinical management of patients with can-
diduria, it is important to consider the removal of13;17(3):283–312
the catheterization system, taking into account that
this measure may resolves approximately 40% of cases,
besides reducing the recurrence of infection (B-I).139 If it
is not possible to remove the system, it is at least recom-
mended to change it.140
Peritoneal candidiasis related to dialysis
Epidemiological aspects
Peritoneal dialysis is a modality of renal replacement therapy
that currently accounts for only 10–20% of dialysis modalities.
It can be performed continuously with an oriented procedure
performed at home or intermittently, which has been com-
pletely abandoned. Among the complications of peritoneal
dialysis, infection ranks second place after cardiovascular
events, and fungal infections account for 2–14% of peritoni-
tis cases.141 The overall mortality in most series ranges from
10 to 25% of cases, and there are a few reports of up to 50%
deaths.142 Among the fungal peritonitis diseases, 80–90% are
caused by Candida, particularly isolates of C. albicans, C. para-
psilosis and C. tropicalis.143 The risk factors for the occurrence
of fungal peritonitis in patients on peritoneal dialysis are not
completely known.144 The basic conditions most commonly
reported in patients with fungal peritonitis include diabetes,
the prior occurrence of peritonitis by other agents and the
previous use of antibiotics.145
Clinical and laboratory diagnosis
Diagnosis is made through clinical signs and symptoms of
peritonitis, which are represented by abdominal pain, dis-
tention, and fever associated with clouding of the dialysis
ﬂuid, whose cell count increases due to the neutrophil count
(>100 leukocytes/mm3). Etiologic evidence is obtained by iden-
tiﬁcation of yeasts in bacterioscopic examination of the
peritoneal ﬂuid, with growth of Candida spp. in culture.141,145
Therapeutic recommendations
The guidelines for the treatment of fungal peritonitis are
based on case reports and open-label studies of limited groups
of patients. Among the key recommendations for the treat-
ment of this complication, the authors suggest that the early
removal of the dialysis catheter is essential to the success of
the therapy (B-II).146
The largest experience in the treatment of fungal peritoni-
tis is with ﬂuconazole or amphotericin B (B-II). Many authors
recommend startingwith amphotericin and completing treat-
ment with ﬂuconazole after clinical improvement (B-II).146
Some authors suggest the use of intraperitoneal ﬂucona-
zole concomitantly with the systemic use of amphotericin B
(C-III).147 The treatment period is usually four to six weeks. It
is essential to monitor the patient by abdominal ultrasound to
rule out collections and to guide the treatment time (B-III).146
There is little reliable information regarding doses of
antifungal agents, but the authors suggest the use of
0.7mg/kg to 1mg/kg/day of amphotericin B and 400mg/day
of ﬂuconazole.148If implantation of a new peritoneal catheter is an option,
this procedure should be performed with a minimum interval
of four to six weeks after the initiation of treatment (C-III).
According to recent studies, at least 40% of patients with
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ungal peritonitis cannot continue with peritoneal dialysis.
nother modality for renal replacement therapy is needed.148
Among the new drugs, caspofungin has experienced the
ost success. It may be considered for patients with poor
esponses to conventional treatment and can be used at
0–100mg/daywith good tolerability (B-II).149 However, in view
f the pharmacological similarities and therapeutic success
f echinocandins, it is believed that all echinocandins can be
sed with these conditions (C-III).
ostoperative peritoneal candidiasis
pidemiological aspects
ostoperative peritonitis caused by Candida species occurs
ith signiﬁcant frequency in the hospital. The majority of
ases are related to episodes of secondary or tertiary peri-
onitis, when cases of acute abdomen perforated by bacterial
eritonitis are subsequently followed by fungal peritonitis.
he perforation of the upper digestive tract is more frequently
ssociatedwith contamination of the peritoneal cavity by Can-
ida compared to the ileum and appendix, occurring in 5–64%
f the perforated cases.150
linical and laboratory diagnosis
he pathological signiﬁcance of Candida spp. isolation in
he peritoneal ﬂuid and drains of patients undergoing
urgery involving manipulation of the gastrointestinal tract
s uncertain. The disruption of the anatomical barrier of
he gastrointestinal tract can lead to the isolation of tran-
itional agents in the abdominal cavity or contamination of
ultures without evolution of the process to properly fun-
al peritonitis.151 Moreover, a case–control study has isolated
andida spp. in the peritonea of patients who developed per-
oration of the gastrointestinal tract that caused increased
ortality.152
In this context, the interpretation of the identiﬁcation of
andida in peritoneal ﬂuid should be evaluated on an individ-
al basis, considering the patient’s clinical conditions. When
andida is identiﬁed in the peritoneal ﬂuid of patients with
omplicated postoperative recoveries, along with persistent
ever and other evidence of peritonitis (for which sepsis is
ikely from an abdominal source), fungal etiology should be
trongly considered. However, in most cases when Candida is
solated in the intraperitoneal ﬂuid cultures of young patients
ithout comorbidities and who have no evidence of systemic
nfection in postoperative uncomplicated appendicitis, the
aboratory ﬁnding is generally transitory with no pathological
eaning.153
herapeutic recommendations
lthough the isolation of Candida in the abdominal cavity is
ssociated with an increase in postoperative complications
nd mortality, the clinical and laboratory data that should
rigger the use of antifungal agents are still a matter of contro-
ersy. If there is suspicion of invasive candidiasis, the patient
hould be treated according to the appropriate therapy for
153ematogenous candidiasis.
The most experience in the treatment of peritonitis
aused by Candida involves the use of amphotericin B
0.7–1mg/kg/day) or ﬂuconazole (400–800mg/day) (B-II).1543;17(3):283–312 297
However, the toxicity of amphotericin B and the limited spec-
trum of ﬂuconazole limit their use in many clinical scenarios.
Taking into account the high rate of success of treat-
ing hematogenous candidiasis observed in patients with
echinocandins and the large sample of surgical patients in
these studies, it is believed that all echinocandins constitute
good alternatives in this condition (B-I).149,154
Respiratory tract candidiasis
Epidemiological aspects
Despite the controversies, there is a general concept in the
literature that Candida pneumonia is an unusual event, par-
ticularly among non-neutropenic patients admitted to ICUs.
The highest incidences of C. pneumonia are documented
among neutropenic patients with hematologic malignancies
or patients undergoing lung transplantation.155
In most cases, C. pneumonia is secondary to a hematoge-
nous invasion. In patients undergoing lung transplantation,
bronchial anastomosis has been identiﬁed as an anatomi-
cal site that is potentially more susceptible to colonization
and invasion by opportunistic fungi, partly due to the relative
ischemia of this region after transplantation. These infections
may be complicated by anastomotic dehiscence and subse-
quent bleeding.156
In ICU patients, especially those undergoing mechanical
ventilation, airway colonization by Candida is found with
relative frequency, but with no pathological signiﬁcance. Tra-
cheobronchial colonization by Candida in ICU patients is the
result of impairment of local defense mechanisms, the pres-
ence of an endotracheal tube, the use of antacids and the
exposure to antibiotics, conditions that lead to substantial
changes in the microbiota of the oropharynx and the gastroin-
testinal and respiratory tracts.157
Clinical and laboratory diagnosis
The isolation of Candida in the respiratory tract of critically
ill patients, even if obtained by bronchoalveolar lavage, does
not allow for the diagnosis of pulmonary candidiasis. In most
cases, this ﬁnding refers to the colonization and/or contam-
ination of the sample during the procedure. Diagnosis by
quantitative culture is not reliable for differentiating colonized
patients from those with pneumonia caused by Candida. Thus,
the ﬁnal diagnosis is dependent on lung biopsy with demon-
stration of the presence of fungal elements in the intima of
the parenchyma and supplemented by a culture of tissue frag-
ments with growth of Candida spp.157 In practice, this is rarely
a deﬁnitive diagnosis.
Therapeutic recommendations
In general, the identiﬁcation of positive cultures for Can-
dida spp. in respiratory tract samples should be considered
evidence of local colonization whose risk of progression to
pneumonia is usually small (B-II).158
Special attention is recommended in the investigation
of neutropenic patients, patients with cancer or hemato-
logic malignancies, along with patients undergoing HSCT or
lung transplantation (B-II).159–161 When a deﬁnitive diagnosis
of pneumonia is reached, the antifungal should be chosen
as discussed in the section involving acute disseminated
i s . 20298 braz j infect d
candidiasis; there may be a choice between echinocandins,
ﬂuconazole or amphotericin B formulations (B-II).149,162
Hematogenous candidiasis
Epidemiological aspects
Hematogenous candidiasis encompasses a wide spectrum of
clinical episodes, including isolates of Candida or cases in
which the fungus is present in the bloodstream and spreads
to one or more organs of the infected host.1 Considering that
most of the data available for hematogenous Candida infection
refer to candidemia, this is the term that will be used in these
guidelines.
It is believed that the majority of cases of candidemia are
acquired via the endogenous route due to the translocation of
the pathogen through the gastrointestinal tract, where there
is rich colonization by Candida spp. in up to 70% of the general
population. Most candidemia events are preceded by colo-
nization by the same species of yeast, which is considered
as an independent risk factor for its development. Genotyp-
ing methods reveal the similarities between colonizing and
infecting strains, conﬁrming the probable endogenous origin
of most of the infections caused by these pathogens.163
Any variables causing injury or imbalance in themicrobiota
of the gastrointestinal mucosa can be facilitators of translo-
cation of Candida spp. to the mesenteric capillaries. Thus,
factors that increase intestinal colonization by Candida (i.e.,
antibiotics, corticosteroids, ileus or intestinal obstruction) or
that determine atrophy or intestinal mucosal damage (i.e.,
prolonged fasting, total parenteral nutrition, hypotension,
surgical procedure, mucositis secondary to chemotherapy or
radiotherapy) may potentiate the phenomenon of transloca-
tion in the gastrointestinal tract.164
Hematogenous infections by Candida spp. can also be
acquired exogenously, either by contamination of invasive
medical procedures, prostheses or contaminated infusion
solutions, such as the colonization of vascular catheters in
central positions.24
Case–control studies conducted during the 1980s and
1990s identiﬁed numerous risk factors associated with the
occurrence of candidemia in hospitalized patients, includ-
ing: the use of antibiotics, colonization by Candida spp. at
different sites, dialysis, major surgery, the use of a CVC in
place, chemotherapy, neutropenia, steroid use and parenteral
nutrition.165,166
There is a wide geographical variation in the documented
etiology patterns of candidemia in different medical centers.
In different studies in tertiary hospitals in the public system
in Brazil, C. tropicalis and C. parapsilosis are prevalent.42,167 Epi-
demiology can vary between different institutions; a recent
study noted higher incidences of C. glabrata in private hos-
pitals of São Paulo, Rio de Janeiro, Salvador, Belo Horizonte
and Curitiba, where the use of ﬂuconazole started in the
1990s. Conﬁrming these data, other series published after
2008 reported rates of candidemia due to C. glabrata and/or
C. krusei above 10% in our setting.43,168 These data reinforce
the importance of implementing programs formicrobiological
surveillance of bloodstream infections for the optimization of
control strategies and the treatment of these infectious com-
plications.13;17(3):283–312
Clinical and laboratory diagnosis
Hematogenous candidiasis is an infectious complication that
should always be investigated in patients with sepsis after
a long period of hospitalization and exposure to risk fac-
tors of candidemia, particularly exposure to broad-spectrum
antibiotic therapy, invasive medical procedures, immuno-
suppressive therapy and parenteral nutrition. Brazilian data
suggest that 40–50%of these patients are in the ICU at the time
of diagnosis. A substantial number of cases have antecedents
involving major surgery, particularly with manipulation of
gastrointestinal tract.9,42
The study of the natural history of patients with can-
didemia shows that some episodes of fungemia must be
transient and self-limited, particularly in non-neutropenic
hosts. However, there are no clinical or laboratory data that
allow the clinician to identify with certainty which episodes
are only transitory and which will lead to cases of dissem-
inated hematogenous candidiasis with tissue invasion and
severe sepsis at the moment of the fungemia diagnosis.
Another important aspect to consider is that in some patients,
infectious complications documented in the viscera appear
weeks or months after a candidemia episode, as occurs in
some cases of retinitis, meningitis, or osteomyelitis caused
by Candida spp.169,170
These guidelines will discuss in detail the clinical man-
agement of three different scenarios of hematogenous
candidiasis:
1. Candidemia: isolation of Candida spp. in the bloodstreams
of patients without clinical and laboratory evidence of
infectious foci in the viscera. In clinical practice, there are
few cases for which there is documentation of the involve-
ment of different organs during the episode of candidemia.
The most frequent clinical pattern of presentation of can-
didemia in adults is only in the presence of fever that is
unresponsive to antibiotics in patients at risk. The fever
may have an insidious onset, without signiﬁcant involve-
ment of the general condition, or may be accompanied by
chills, myalgia, hypotension and tachycardia. Eventually,
some patients develop hypothermia and other evidence of
sepsis.2
2. Acute disseminated candidiasis: documentation of the
presence of concomitant fungemia infection in other
organs. When present, the acute spread of candidemia
to the organ involves the skin and eye. However, the
spread of infection to multiple organs may occur, includ-
ing cases of pyelonephritis, endocarditis, osteoarticular
involvement and involvement of the central nervous sys-
tem, among others. The appearance of skin lesions can
be the ﬁrst clinical manifestation of invasive disease and
is a marker of disease spread. Skin lesions may affect
approximately 8% of cases, presenting typically as small
nodules or erythematous or purpuric maculopapules, but
other morphological features of lesions are described.
Systemic candidiasis with skin lesions is particularly fre-
quent in neutropenic patients with candidemia due to C.
171tropicalis. In more recent studies, systematic evaluation
of fundoscopy performed by an ophthalmologist suggests
that ocular involvement occurs in up to 16% of patients
with candidemia, being 2–9% of cases of chorioretinitis and
201braz j infect d i s .
1% of cases of endophthalmitis.172,173 Symptoms include
blurred vision, bulbar scotomas and pain. The ophthal-
mologic abnormalities are characterized by cotton wool
lesions in the retina and vitreous humor, multiple reti-
nal hemorrhages, Roth spots, and uveitis. However, all
ocular structures may be affected. When endophthalmitis
occurs, therapy is difﬁcult, and the incidence of sequelae
is high. The recognition of ocular involvement in patients
with candidemia is crucial because the treatment should
be administered for a longer period and may eventually
require surgery to control theprocess. Thediagnosis should
be made early, before the involvement of the vitreous.174
In adults, Candida meningitis usually results from the con-
tamination of a neurosurgical procedure and is rarely
documented as a complication of candidemia. However,
according to data from autopsy series (which may not rep-
resent the general population), patients with sepsis who
develop Candida fungal lesions in the central nervous sys-
tem have died in up to 20% of cases.175 Endocarditis caused
byCandidausually occurs as a post-surgical complication of
valve replacement surgery and in intravenous drug users,
particularly those who use heroin. Endocarditis is rarely
reported as a single candidemia complication in a patient
who did not undergo cardiac surgery.175 Osteoarticular
involvement of candidemia is quite rare but may arise as
a late complication (more than one year after the alleged
episode of fungemia). Bone involvement is recognized by
local pain, fever and radiological ﬁndings consistent with
osteomyelitis.175
The diagnosis of hematogenous candidiasis in at-risk
patients requires careful clinical examination to identify
skin lesions and ocular changes consistent with can-
didemia, in addition to blood cultures.
Blood cultures are a mandatory procedure in any patient
with clinical suspicion of systemic infection by Candida,
and some care must be taken to optimize the recovery of
the agent:
• Follow appropriate antisepsis at the puncture site, and
remember that the antiseptic must be allowed to act for
a few minutes before performing the collection.
• It is desirable that blood cultures beperformedbeforeuse
of antimicrobials, or if this is not possible, blood should
be harvested in the period preceding the administration
of daily doses of drugs.
• Blood volume and number of samples are crucial for a
good yield of blood cultures; it is recommended that at
least two samples per episode of sepsis be collected and
that each sample contain at least 20mL of blood (divided
into two blood culture bottles per sample).176
• Conventional aerobic bottles for automated blood cul-
tures allow the growth of Candida species. However, the
performance of aerobic vials may vary between differ-
ent products. Bactec system vials have lower sensitivity
and a longer time for fungal growth than bottles from
the BacTAlert system. There are no appreciable differ-
ences between these products when using bottles with
selective media for fungi.177
• It is essential that blood cultures be processed by auto-
mated systems, which have better sensitivity and allow
for quicker isolation of the agent.3;17(3):283–312 299
It is important to remember that there is a direct rela-
tionship between mortality and the time to onset of
treatment of candidemia. Accordingly, every effort should
be made for early recognition of patients with hematoge-
nous candidiasis.102
Given the low frequency of the occurrence of visceral
lesions in the majority of adult patients with candidemia,
the investigation of fungal endocarditis (echocardiography)
and lesions in other organs (abdominal imaging) should
be reserved for patients who persist with isolation of
Candida in blood cultures despite appropriate antifungal
therapy or who show signs of clinical deterioration and
signs/symptoms suggestive of infection in the abdominal
cavity and/or endocarditis. In turn, fundoscopic examina-
tion should be performed in all patients with candidemia
and visual symptoms. In patients with candidemia but
no visual symptoms, it is recommended to perform fun-
doscopy one week after the initiation of therapy to increase
the sensitivity of eye lesion detection.102,174
3. Chronic disseminated candidiasis (CDC): complication
documented in patients with neutropenia that develop
suppurative lesions predominantly localized in the liver
and spleen (but may occur in other organs, particularly
the kidney) that manifest after the recovery of neutrophils
and capacity of the host inﬂammatory response. High fever
is the most important symptom and occurs in almost
all patients; it is associated with anorexia, weight loss,
pain in the right hypochondrium, nausea and vomiting.
Hepatosplenomegaly is identiﬁed in half of the cases. A sig-
niﬁcant increase in serumalkaline phosphatase,which can
be up to ten times the baseline, is the most important labo-
ratory ﬁnding for CDC diagnosis in suspected patients with
persistent fever after neutrophil recovery.175
A diagnosis can be conﬁrmed with ultrasound, comput-
erized tomography, magnetic resonance imaging or positron
emission tomography (PET-CT) of the abdomen, along with
ﬁndings of swelling of the affected organs and the presence
of multiple abscesses in the liver, spleen and/or kidneys.
Blood cultures are usually negative, and if a directed biopsy
is conducted, necrotic cellular elements can be identiﬁed,
and fungal elements are absent. In this context, microbiolog-
ical conﬁrmation of the process is rarely obtained. In most
cases, the patient is treated according to the epidemiological
and clinical ﬁndings, together with the laboratory evidence
of CDC represented by abscesses in abdominal imaging and
high levels of alkaline phosphatase.175,178 It is important to
remember that this situation can occur in infections by other
fungi, including yeast (e.g., Trichosporon) and molds (Fusarium,
Scedosporium, etc.).
Therapeutic recommendations
The deﬁnition of the best therapeutic strategy to be adopted
for patients with hematogenous candidiasis should consider
the aspects described below:179
• Presence of infectious complications in organs: the occur-
rence of endophthalmitis, osteomyelitis, endocarditis and
CDC are examples of clinical conditions for which antifun-
gal therapy should be extended for periods of four weeks
i s . 20300 braz j infect d
to six months. If prolonged therapy is needed, oral drugs
should be chosen.
• Severity of the clinical presentation of the case: this issue
is controversial, but patients with organ failure are usually
treated initially with fast-acting antifungal drugs; ﬂucona-
zole is generally saved for a second event when there is
an initial clinical response and identiﬁcation of the Candida
species.
• DeterminationofCandida species: non-albicans speciesmay
exhibit lower susceptibility to ﬂuconazole, requiring dose
adjustment or a change in medication.
• Riskof renal toxicitywhileusing conventional amphotericin
B: the occurrence of acute renal failure in patients in ICUs
with renal dysfunction, elderly patients and those receiving
other nephrotoxic drugs.
• Previous exposure to antifungal prophylaxis regimens
and/or empirical therapy: facing a breakthrough infection in
a patient exposed to an antifungal agent, a change of ther-
apeutic class is indicated until the involved Candida species
and the susceptibility proﬁle of the agent are conﬁrmed.
• Presence of an intravascular catheter in a central position:
the clinical management of this aspect will be discussed in
another section.
• The need for surgical removal of the infectious focus: cases
of osteomyelitis and endocarditis are examples of clinical
situations in which surgical cleaning (or valve replacement)
should be considered in the therapeutic management of
patients.
We currently have the following drugs available for the
treatment of invasive candidiasis: amphotericin B and its for-
mulations, ﬂuconazole, voriconazole and echinocandins.
Candidemia in non-neutropenic patients
In the last two years, there have been important changes
in the epidemiology of candidemia. Several medical cen-
ters have reported fungemia rates greater than 10% in adult
patients involving species resistant to ﬂuconazole, particu-
larly C. glabrata and C. krusei.43,168,180
Moreover, it is known that the rates of persistent Candida
in patients treated with ﬂuconazole are far superior to those
of patients treated with drugs most effectives, like echinocan-
dins or formulations of amphotericin B.32,35
In the only study comparing an echinocandin to ﬂucona-
zole, success rateswere signiﬁcantly higher in patients treated
with anidulafungin, even in infections susceptible to ﬂucona-
zole (C. albicans and C. tropicalis).32 However, for the three
echinocandins available in the Brazilian market, there have
been substantial price reductions in the daily treatment doses
used with this therapeutic class.
A meta-analysis study evaluating therapeutic results of 7
randomized clinical trials performed in 1.915 patients with
candidemia/invasive candidiasis involving three therapeutic
classes reported that treatment with echinocandins was asso-
ciated with decreased mortality.181Given the poor prognosis of this infection in Brazil (50%
associatedmortality inmost series), thehigh rate of successful
clinical and laboratory treatment of candidemiawhenabroad-
spectrum antifungal drug with fungicidal activity is used from13;17(3):283–312
the beginning of treatment, and the lower rates of echinocan-
din toxicity compared to any formulation of amphotericin B,
we understand that the best option for initial treatment of
this infectious complication is one of the three echinocandins:
anidulafungin (A-I), caspofungin (A-I) or micafungin (A-I).30–32
Despite the high MIC values observed with echinocandin
when tested against C. parapsilosis, therapeutic results are
satisfactory in clinical trials, with no signiﬁcant differences
regarding success rates when compared to infections by other
species ofCandida.16,34 However,with persistent positive blood
cultures for C. parapsilosis, it is recommended that another
class of antifungal be started (B-II).
The best use of ﬂuconazole should be considered in
sequential therapy to complete a minimum period of 14 days
of treatment after determining the etiological agent and upon
documentation of a favorable clinical response to treatment
with echinocandins (B-I).182
The best use of voriconazole is as an oral sequential
therapy in patients infected with strains resistant to ﬂucona-
zole and susceptible to voriconazole and as a therapeutic
approach for patients with central nervous system involve-
ment/endophthalmitis (B-II).81,190 This product should be
contraindicated in breakthrough infections after ﬂuconazole
therapy and/or invasive infections caused by C. glabrata and
C. krusei and in view of the possibility of cross-resistance and
limited efﬁcacy in this scenario (B-III).44,81
In view of the renal toxicity of amphotericin B deoxy-
cholate, this drug should be avoided in ICU patients,
particularly those exposed to conditions or other nephrotoxic
drugs (A-I).183
Fluconazole may be an alternative therapy in clinically sta-
ble patients whose infections are considered minor, who were
not exposed to regimens of prophylaxis with triazoles, and
who are admitted to medical services exhibiting low inci-
dences of infections caused by C. glabrata and C. krusei (B-I).184
Medical centers with rates of incidence exceeding 10% of the
ﬂuconazole-resistant strains should not use ﬂuconazole in
any patient before the agent is identiﬁed (C-III).
Lipid formulations of amphotericin B are an alternative
therapy for candidemia, but they have greater renal toxicity
than echinocandins. The only lipid formulation in the treat-
ment of Candida assessed in a randomized and comparative
study with echinocandin was the liposomal formulation of
amphotericin B, indicated at a dose of 3mg/kg/day for the
treatment of adults (B-I).31
The lipid complex of amphotericin B has been used
in patients with candidemia, but only in open-label non-
comparative studies using doses ranging from 3mg/kg/day
and 5mg/kg/day (B-II).185
Lipid formulations of amphotericin B are alternatives for
patients who: are unresponsive to echinocandins, are intol-
erant to this therapeutic class, or develop endocarditis or
meningitis (B-III).102
Patients with endophthalmitis may not respond to
echinocandins, given its low penetration in the eye. In this
context, better results are expected with ﬂuconazole or
173voriconazole (B-II).
With respect to the time of treatment in all randomized
trials conducted with antifungal agents in the last decade,
the duration of antifungal therapy was at least 14 days after
201
n
t
b
n
t
t
r
a
o
C
P
b
t
t
b
(
c
a
p
a
p
t
o
g
t
a
t
w
(
e
m
p
c
P
A
e
U
i
v
t
f
f
t
P
I
i
f
I
wbraz j infect d i s .
egative cultures and the disappearance of signs and symp-
oms of hematogenous candidiasis.102 In this sense, serial
lood cultures must be collected until the infection site is
egative, and it is recommended to repeat sampling on the
hird and ﬁfth day after initiation of therapy (at a minimum)
o evaluate the success of the microbial treatment (B-III).102
Cases of endocarditis, osteomyelitis, meningitis, or CDC
equire longer treatment; it is very important to check the
vailability of antifungal drugs with good bioavailability for
ral use (B-II).102
andidemia in neutropenic patients
atients with neutropenia should be treated with drugs with a
road-spectrum antifungal drug with fungicidal activity from
he beginning of treatment (A-II).186 Given the risk of renal
oxicity with conventional amphotericin B, this drug should
e avoided in this scenario (B-I).183 Therefore, echinocandins
A-I), liposomal amphotericin B (B-I) and amphotericin B lipid
omplex (B-II) are considered alternatives.187,188
Randomized trials of candidemia involving caspofungin
nd micafungin included approximately 10% neutropenic
atients. Although there are no data on the performance of
nidulafungin in the treatment of candidemia in neutropenic
atients, there is no evidence of pre-clinical or clinical order
o suggest that echinocandins have differences in their rates
f therapeutic success (B-III).
Given the higher incidence of infections caused by C.
labrata and C. krusei in patients with cancer, along with
he fact that large percentages of patients with neutropenia
re exposed to ﬂuconazole prophylaxis, the recommenda-
ion is that the primary treatment of candidemia in patients
ith cancer and neutropenia not be performed with triazoles
B-II).189 The treatment time must meet the same criteria
stablished for non-neutropenic patients (B-I).102
Infections involving multiple organs or systems must
eet the same recommendations given for non-neutropenic
atients, alongwith care for patients referred for C. parapsilosis
andidemia treated with echinocandins (B-II).16,34
atients with evidence of endophthalmitis
ll patients with candidemia should have at least one dilated-
ye examination performed by an ophthalmologist (A-II).102
pondiagnosis of endophthalmitis, the drugs better penetrate
nto the eyeball are ﬂuconazole and voriconazole (B-III).190,191
Early intervention with partial vitrectomy and/or an intra-
itreal antifungalmay benecessary in severe cases (B-III).192 In
hese cases, we recommend antifungal therapy for a period of
our to six weeks, with monitoring by an ophthalmologist for
urther characterization of the time of treatment and response
o therapy (A-III).102
atients with evidence of endocarditis
n these cases, the greatest experience in the literature
nvolves systemic therapy with an amphotericin B lipid
ormulation due to the possibility of using high dosages (B-
I).193 Alternatives include echinocandin (B-II) andﬂuconazole,
hich should be used when the Candida species is susceptible3;17(3):283–312 301
and the patient is clinically stable (B-III).194–196 Although
amphotericin B is considered an effective alternative, in view
of its potential toxicity and the treatment duration required,
its use should be avoided (B-II).183 A valve replacement is rec-
ommended, and systemic therapy should continue for at least
six weeks after valve replacement (B-III).197
Patients with chronic disseminated candidiasis
Given the low incidence of this complication, there are no
comparative data regarding efﬁcacy and tolerability between
the different antifungals.
The treatment of this condition is always long, so starts
with a broad-spectrum fungicidal drug until clinical improve-
ment is achieved, which is followed by oral ﬂuconazole for
three to six months (A-III).198 The antifungal should be used
until complete resolution of the abscess, as detected by imag-
ing (A-III).198
The greatest experience in treating patients with CDC
involves amphotericin B formulations (B-II).198 In case of infec-
tion control and as long as the patient continues receiving
antifungal drugs, there are no contraindications for starting
a new cycle of chemotherapy or for the transplantation of
hematopoietic stem cells (B-II).199,200
The therapeutic options are amphotericin B deoxycholate
at a dose of 0.6–0.7mg/kg/day (B-II); an amphotericin B lipid
formulation at a dose of 3–5mg/kg/day (B-II)201; ﬂuconazole
6mg/kg/day in stable and non-neutropenic patients who have
not previously used ﬂuconazole (B-II)202,203 and echinocandins
in the usual doses (B-II).204
As manifestations of CRC result from an exaggerated
inﬂammatory response, the use of corticosteroids as an adju-
vant therapy may be useful. In a series of cases, patients who
received corticosteroids experienced rapid resolution of fever
and general symptoms (B-II).178
Management of a central venous catheter
Most patients with candidemia have one venous catheter in
the central position upon diagnosis. The reason for removal of
the CVC in patients with candidemia is the fact that Candida
can colonize the CVC, producing a bioﬁlm, and lack of removal
may result in persistence of a focus of infection. Several ret-
rospective studies have analyzed the impact of CVC removal
on outcomes such as duration of candidemia and mortality;
the majority of these studies reported lower mortality rates
when the CVC was removed.205–210 These studies form the
basis for recommendations to remove the CVC in the guide-
lines of candidemiamanagement published in recent years.102
However, these studies have several limitations, including the
lack of multivariate analysis, in particular severity scores, the
inclusion of early deaths and, most importantly, the absence
of setting a time for the withdrawal of the CVC.
A recently published study analyzed 842 episodes of can-
didemia in adults and conducted a sub-analysis of two
randomized trials of candidemia treatment with echinocan-
dins (caspofungin or micafungin) or liposomal amphotericin
B. We investigated the effect of early removal (24 or 48h after
initiation of candidemia treatment) in six outcomes: success
rate of candidemia treatment, candidemia persistence rate,
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and mortality rates of Candida applicants at 28 and 42 days.
None of the six outcomes was inﬂuenced by early removal of
the CVC (both in 24h and in 48h).211 Based on this study, adult
candidemia and the early removal the CVC (24–48h after the
start of treatment) cannot be recommended if the patient is
receiving an echinocandin and liposomal amphotericin B (B-
II). In this case, removal of the CVC is recommended if there
is persistent (>72h) isolation of Candida despite treatment.
However, the group consensus considered waiting 72h
after the initiation of antifungal therapy to deﬁne the need
for removal of the CVC, as this cannot be the recommended
approach in some scenarios for speciﬁc patients. In this sense,
in non-neutropenic critically ill patients who have severe sep-
sis, as well as in breakthrough cases of candidemia in patients
receivingmore than 3 days of a systemic antifungal agentwith
activity against the pathogen isolated, early removal of the
CVC can be considered (C-III).
Empirical therapy
Neutropenic patients
Empirical antifungal therapy is instituted in neutropenic
patients with fever and neutropenia that persist for a period
of four to six days after initiation of broad-spectrum antibi-
otics. This practice was instituted in the 1980s and 1990s, and
some randomized trials have been published initially testing
this strategy after comparing different agents.212,213 Accept-
able options for empirical therapy that have been tested in
randomized trials are lipid preparations of amphotericin B,
caspofungin and voriconazole.214,215,187 More recently, empir-
ical antifungal therapy has been replaced by another strategy
called preemptive therapy, which consists of starting antifun-
gal therapy because of fever and other signs of infection.216
This strategy is more relevant when there is suspicion of
infection by ﬁlamentous fungi (Aspergillus spp., Fusarium spp.
and others). Some biomarkers have been tested, including
galactomannan (Aspergillus spp.)217 and 1.3 beta-d-glucan for
Candida spp., Aspergillus spp. and other fungi.218
Regarding invasive candidiasis/candidemia, the most
important issue to consider in a neutropenic patient with
persistent fever despite antibiotic therapy is to assess the
risk of infection. There are three parameters to be evalu-
ated: the use of ﬂuconazole in prophylaxis as well as the
presence of gastrointestinal mucositis and a CVC. In addi-
tion to the risk, another parameter to be considered is the
need for coverage of ﬁlamentous fungi. Patientswith profound
neutropenia (>100 cells/mm3) lasting more than ten days are
those with increased risk for developing ﬁlamentous fungal
infection.216
Recommendations for empirical therapy for
candidemia/invasive candidiasis in neutropenic patients
Amphotericin B deoxycholate should not be used because
these patients often have other risk factors for nephrotoxicity,
including the underlying disease (e.g., multiple myeloma), its
treatment (i.e., anticancer drugs, tumor lysis syndrome) and
the use of other nephrotoxic agents (i.e., diuretics, antibiotics)
(A-II).18313;17(3):283–312
Patients who are receiving prophylactic ﬂuconazole, do not
have gastrointestinal mucositis and who are not at risk of
infection by ﬁlamentous fungi may not receive empirical anti-
fungal therapy (C-III).219
Patients who are not receiving ﬂuconazole and who are
not at risk of infection by ﬁlamentous fungus should receive
ﬂuconazole (B-I).219 Patients who are receiving ﬂuconazole
prophylaxis, yet the clinician considers the possibility of inva-
sive candidiasis, should receive empirical therapy with an
agent from another therapeutic class (i.e., a lipid preparation
of amphotericin B or an echinocandin – caspofungin or mica-
fungin) (B-II).219
Non-neutropenic patients
Candidemia is an important complication of critically
ill patients and is associated with high morbidity and
mortality.220,221 Recent studies have shown that the delay in
initiating appropriate treatment in patients with candidemia
signiﬁcantly increases mortality.222,223
Approximately 40–50% of candidemias occur in patients
admitted to the ICU. This population of patients has a high
risk ofmortality because they are clinically unstable. Thus, ICU
patients at high risk for candidemia/invasive candidiasis may
beneﬁt fromearly initiationof anappropriate antifungal.How-
ever, unlike in neutropenic patients, empirical therapy has not
been adequately tested in non-neutropenic patients, as there
are no validated tools to identify patients at risk and because
it is difﬁcult to deﬁne outcomes to assess the effectiveness of
the therapy.
Despite these limitations, some attempts have been made
to identify patients with invasive candidiasis in units of
severely ill patients.224–228 These scoring systems use clinical
information with or without data from Candida colonization
and yielded a reasonable correlation with the occurrence of
candidemia/invasive candidiasis.More recently, twobiological
markers have been tested for the early diagnosis of can-
didemia/invasive candidiasis: 1-3 beta-d-glucan and PCR. In a
study in surgical patients, the evaluation of 1-3 beta-d-glucan
in the plasma of patients colonized with Candida was use-
ful to trigger the onset of empirical antifungal.229 In another
study, a PCR assay was tested in 225 patients at high risk
for candidemia. Using blood culture as the gold standard,
the sensitivity and speciﬁcity of PCR were 72.1 and 91.2%,
respectively.230
Recommendations for empirical therapy for
candidemia/invasive candidiasis in non-neutropenic patients
Physicians should consider the use of empirical antifungal
therapy in critically ill patients with risk factors for can-
didemia and clinical manifestations of infection that are not
responding to treatment for bacterial infections (C-III).
The choice of antifungal drug for empirical therapy should
be based on the same criteria for the selection of appropriate
antifungal treatment for candidemia (see speciﬁc section).
To support the clinician in the task of selecting patients
for empirical antifungal therapy, as experts, it is our opinion
that this therapeutic strategy has a greater chance of success
when used in ICU patients with sepsis that is unresponsive
to antibiotics (excluding other causes of FOI) who have been
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xposed to three or more risk factors for candidemia for at
east 4–7 days of intensive care, particularly thosewithCandida
olonization in non-sterile sites and a history of major surgery
n the last two weeks (C-III).
rophylaxis
eutropenic and hematopoietic stem cell transplant
atients
nvasive candidiasis/candidemia is a frequent complication
n neutropenic patients and recipients of HSCTs who do not
eceive prophylaxis. In neutropenic patients, the frequency
aries depending on the patient receiving chemotherapy.
he risk factors include neutropenia, the use of a CVC and
rimarily gastrointestinal mucositis.231 Thus, patients receiv-
ng intensive chemotherapy are those with increased risk of
eveloping invasive candidiasis. In HSCT, invasive candidia-
is/candidemia typically occurs in two stages: ﬁrst, early after
ransplantation, the risk factors are the same as patients
eceiving chemotherapy, as in this phase, they also have a
atheter and neutropenia, and mucositis may develop. After
he recovery of the blood marrow, autologous HSCT recipients
arely develop invasive candidiasis/candidemia. The receptors
f allogeneic HSCT can present with invasive candidiasis if
hey develop chronic graft versus host disease (GVHD) in the
I tract.
Several randomized trials testing different agents have
een developed for prophylaxis of invasive candidia-
is/candidemia in patients receiving both chemotherapy
nd HSCT. The agents that exhibited efﬁcacy were ﬂu-
onazole, itraconazole oral solution (but not capsules),
oriconazole, posaconazole, micafungin, caspofungin and
ntravenous amphotericin B. However, many studies have
hown no beneﬁts, either due to methodological problems
low numbers of patients) or because the study population
ad a high risk of developing invasive candidiasis.232
ecommendations for prophylaxis for candidemia/invasive
andidiasis in neutropenic patients receiving HSCT
SCT. Fluconazole is the drug of choice for prophylaxis of
nvasive candidiasis in the period of neutropenia in recipients
f allogeneic HSCT and can be established at the beginning or
he end of the conditioning regimen (A-I).233,234 The standard
ose is 400mg/day, but there is evidence in a randomized
tudy that 200mg/day is also effective (B-I).235 An alternative
o ﬂuconazole is micafungin, but its use is limited by the need
or venous access and its high cost (B-I).236
Itraconazole oral solution (not available in Brazil) was also
ffective, but its use is limited by the high frequency of gas-
rointestinal side effects (C-I).237,238
Voriconazole is an alternative that can be used when you
eed coverage for ﬁlamentous fungi based on a comparative
tudy with ﬂuconazole (B-I).239
Options for prophylaxis of invasive candidiasis in the post-
240,241icks are voriconazole and posaconazole (B-I).
The risk of invasive candidiasis/candidemia is much
ower in recipients of autologous HSCT. Thus, prophylaxis
s not routinely recommended (C-III). However, prophylaxis3;17(3):283–312 303
(ﬂuconazole) may be indicated in some situations, such as
whenmanipulation of the graft occurs, when severemucositis
is expected, in patients who received ﬂudarabine or cladrib-
ine or in those with MBL (mannose-binding lectin) deﬁciency
(B-III).170
Neutropenia. The results of randomized trials testing ﬂucona-
zole in neutropenic patients are not as effective as in HSCT,
especially because this population is more heterogeneous.232
In general, the more intensive the chemotherapy regimen
is, the higher the risk of invasive candidiasis. Thus, patients
with acutemyeloid leukemia/myelodysplasia receiving remis-
sion induction chemotherapy may beneﬁt from prophylaxis.
Although ﬂuconazole is the drug of choice for the prevention
of invasive candidiasis, these patients also have a high risk
of ﬁlamentous fungi; thus, posaconazole (200mg orally three
times a day) may be preferred (A-I).241
For the prevention of invasive candidiasis, itraconazole oral
solution (not available in Brazil) can be used, but it has the lim-
itation of gastrointestinal toxicity (C-I). In a meta-analysis of
13 randomized trials, itraconazole oral solution also prevented
the occurrence of invasive aspergillosis, and in ten studies,
TCTH receptors were also included.242
Caspofungin was also tested in a randomized study; it is
an option, with the exception of requiring venous access for
administration (C-I).243
Prophylaxis for invasive candidiasis/candidemia in sit-
uations out of remission induction for acute myeloid
leukemia/myelodysplasia is not routinely recommended (C-
III). However, in special situations, such as after remission
induction regimens for acute lymphoid leukemia in high risk
patients, prophylaxis may be useful (C-III).
Solid organ transplanted patients
Solid organ transplant recipients represent a set of hosts
susceptible to infectious events, which result from the inter-
actionbetweenendogenous immunosuppression (i.e., uremia,
diabetes, liver failure), iatrogenic immunosuppression (result-
ing from the use of medications to prevent rejection
episodes) and surgical procedures and their inherent risks.
Among infectious events, fungal infections are important
because they usually depend on many immunodepression
states.
However, the group of transplanted solid organs is het-
erogeneous with respect to the variables that lead to
immunosuppression and, therefore, with respect to the actual
state of the resulting immunosuppression, which leads to
different rates of fungal infection and different prevalence,
including Candida infections.
Epidemiology, clinical signiﬁcance and recommendations
for prophylaxis for candidemia/invasive candidiasis in solid
organ transplant patients.
Kidney transplantation
Renal transplantation is the most frequent solid organ trans-
plantation and the least technically complex from the surgical
point of view because it is an extraperitoneal surgery of short
duration.
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Renal transplantation is the solid organ transplantation
with the lowest rate of invasive Candida infections and the
one in which the clinical repercussion is least signiﬁcant.
Approximately 50% of yeast infections are caused by Candida
species. Of these, over 70–80% represent urogenital infec-
tions (especially candiduria, which occurred in 11% of patients
in a retrospective study) or esophagogastric infections. Only
0.5–5% of the infections occur in the form of candidemia or
disseminated candidiasis.244
The most prevalent infections (i.e., UTI and esophagitis)
are associated with low morbidity and are infections of sec-
ondary importance in the spectrum of fungal infections in
kidney transplants.
Due to the benign nature of Candida infections in this group
and the low rate of candidemia, there is no formal recommen-
dation for chemoprophylaxis.
Exceptions are made for situations in which there is a UTI
in the donor at the time of transplantation because there
are anecdotal reports of transmission to the donor with seri-
ous consequences (i.e., loss of graft anastomosis). Prophylaxis
depends on exact timing, and single-agent treatment is not
established (C-III).245
Liver transplantation
Liver transplantation, the second most frequent solid organ
transplantation, is related to high rates of fungal infections
(30–40%) mainly due to the complexity of the surgical pro-
cedure, which requires an approach through the abdominal
cavity and often the bowel, factors known to be related to the
occurrence of Candida infections.
Among fungal infections, Candida infections represent 80%
of the total events, and candidemia (40%), peritonitis and
intracavitary abscesses are the most common manifestations.
Most events occur before the sixth post-transplantmonth, and
there has been a reduction in the frequency of Candida over the
past years, which has been attributed to improved practices
and surgical results.246
Risk factors that distinguish patients at higher risk for
invasive candidiasis are retransplantation, dialysis and kidney
failure, the need for large volumes of blood products during
surgery, antibiotic therapy before transplantation and biliary-
enteric anastomosis.246
Contrary to what is observed following kidney transplants,
invasive Candida infections are associated with reduced
patient survival and considerable morbidity.
In this patient population, randomized, placebo-controlled
trials have attempted to reduce invasive candidiasis, reﬂect-
ing the importance of the event. At least six randomized trials
(using ﬂuconazole, itraconazole or liposomal amphotericin)
and a meta-analysis of these combined studies are available
in the medical literature.247
The results of this meta-analysis, which involved total
transplanted groups (with no selection criteria for special
groups or subgroups), show total reduction of fungal infec-
tions, particularly invasive fungal infections (without speciﬁc
reference to reducing candidemia), consistent with the results
of each individual study and regardless of the antifungal agent
used. However, a reduction in mortality is not demonstrated.
There is a need for treatment of 11.8 patients to prevent one
invasive fungal infection.24713;17(3):283–312
Some authors, having identiﬁed heterogeneity in patients
and the presence of speciﬁc risk factors that identify high-
risk populations, advocate focusing on this population as a
target for prophylactic therapy.248 However, these recommen-
dations are based on observational and uncontrolled studies,
decreasing the strength of the recommendation.
The focus on higher-risk patients is bolstered by the
demonstration (from controlled studies) that prophylaxis can
lead to side effects, such as the selection of non-albicans
strains with greater potential for resistance to azoles.
With the above data available, it is the opinion of this con-
sensus group that antifungal prophylaxis is recommended in
liver transplant recipients at greatest risk, recognizing its clini-
cal importance, frequency and thedifﬁculty of establishing the
diagnosis in advance. According to the criteria of cost, toxicity
and acceptance, we also recommend the use of ﬂuconazole as
the drug of choice.249
Find below the speciﬁc recommendations.
• Patients at risk for whom prophylaxis should be rec-
ommended in the ﬁrst month after transplantation: the
existence of at least two of the following risk factors in
the ﬁrstmonth after transplantation: retransplantation, the
need for dialysis, the use of antibiotics and wide biliary-
enteric anastomosis (B-II).
• Prophylactic scheme: ﬂuconazole 200mg (minimum dose)
IVwith the possibility of using orally for up to threemonths,
individualized according to the patient’s clinical condition
(i.e., state of immunosuppression, presence in ICU and per-
sistence of risk factors) (B-II).
• Using this strategy, monitor the levels of calcineurin
inhibitors (tendency to increase in serum) and check for
interactions with other azoles (A-II).
Pancreas/kidney transplantation
This transplantation modality is also frequently associated
with fungal infections because it is performed in diabetic
patients and also because of the complexity of the surgery,
which involves handling of the intestinal tract.
Over 90% of events are caused by Candida species in the
form of intra-abdominal infections with or without concomi-
tant candidemia. As is the case with liver transplantation,
invasive Candida infections are associated with both reduced
grafts and patient mortality.250
Although the frequency and clinical impact of Candida
infections are very similar with respect to what occurs in
liver transplantation, there are no randomized studies evalu-
ating the effectiveness of prophylactic antifungal drugs. There
are also no studies reporting speciﬁc risk factors for the
occurrence of fungal infections in this group of transplant
recipients. There is only one controlled observational study
with historical groups showing lower rates of Candida infec-
tionswith ﬂuconazole 400mg/day for seven days. The practice
is widespread in groups that perform pancreatic transplanta-
tion, and there is currently little room for the proposition of
controlled studies with placebo.251
It is the opinion of this consensus that prophylaxis should
be restricted, recognizing the importance of the event and to
curb the excessive use of prophylaxis. Fluconazole can be used
in a similar scheme to that used for liver transplantation (C-II).
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horacic transplantation (heart, lung, heart/lung)
n this group of patients, infections occur in 2.2% of patients
ndergoing heart transplantation and in 9% of patients under-
oing lung or heart/lung transplantation. However, unlike
hat happens with other types of solid organ transplanta-
ions, there is a high prevalence of infections by ﬁlamentous
ungi with high mortality. Candida infections occur in 30%
f fungal infections, mainly in the form of hematogenous
andidiasis.252
The low incidence of serious fungal infections in heart
ransplant does not indicate the use of speciﬁc prophylaxis
n this population.
With respect to lung transplantation, the focus is to pre-
ent the occurrence of ﬁlamentous fungi; preventing Candida
nfection is a less-important goal. Thus, this consensus does
ot suggest prophylaxis for Candida in this group of patients
ut reinforces the importance of anti-Aspergillus prophy-
axis, which has been adopted by 75% of lung transplantation
enters.253
ntestinal transplantation
ntestinal transplants are performed infrequently but are
ssociated with high rates of Candida infections by extensive
anipulation of the intestinal tract.
Data are scarce regarding prophylaxis in this group; treat-
ent with ﬂuconazole should be considered in high-risk
atients.
eneral recommendations
here is no indication for routine prophylaxis against Candida
n renal transplant patients (B-II). There is evidence for the
se of prophylaxis for Candida in liver transplantation with
eduction in invasive events but not in mortality (B-II).
Liver transplant patients should receive prophylaxis with
uconazole for one to three months (B-II).
The same level of evidence exists for the use of ﬂuconazole
n kidney/pancreas or intestinal transplants, but the use of
uconazole is suggested for high-risk patients (C-III).
There is no indication for routine prophylaxis against Can-
ida in transplanted heart and/or lung patients (B-II).
on-neutropenic patients in the ICU
here are four randomized and well-designed clinical trials
llustrating the beneﬁt of the use of ﬂuconazole in terms of
eduction of invasive Candida infection in the ICU, particularly
or surgical patients. Despite studies that show the effective-
ess of prophylaxis with ﬂuconazole in terms of reduction
f invasive Candida infections (but not mortality), it is not
ossible to establish criteria that are universally applicable
or the selection of patients undergoing prophylaxis with
his triazole. This fact is due to the large heterogeneity of
linical characteristics in patients admitted to the ICU from
ifferent medical centers and the variations in the incidence
ates of candidemia in hospitals. Whereas most medical cen-
ers have incidence rates of candidemia on the order of 1%
mong patients in the ICU, 100–200 critically ill patients must
e exposed to prophylaxis with ﬂuconazole to prevent one
pisode of candidemia. In this context, until new criteria for
electing patients at high risk (chance >10% for event) for3;17(3):283–312 305
candidemia are validated, this practice has questionable bene-
ﬁts, as it is associatedwith increased risk for adverse effects; it
also contributes to the development of resistance to triazoles
and can lead to increased health care costs.254–256
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